Disease on EC 3.5.2.17 - hydroxyisourate hydrolase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Spontaneous
Proteomic analysis on the alteration of protein expression in the placental villous tissue of early pregnancy loss.
Acquired Immunodeficiency Syndrome
The acute-phase protein response to human immunodeficiency virus infection in human subjects.
Acute Kidney Injury
Gene Microarray Integrated with High-Throughput Proteomics for the Discovery of Transthyretin in Rhabdomyolysis-Induced Acute Kidney Injury.
Adenocarcinoma
Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma.
Serum biomarker panels for the diagnosis of gastric adenocarcinoma.
Adenocarcinoma of Lung
CM156, a sigma receptor ligand, reverses cocaine-induced place conditioning and transcriptional responses in the brain.
Adenoma
Detection of colorectal adenoma and cancer based on transthyretin and C3a-desArg serum levels.
Albuminuria
Albumin/creatinine (uACR) and protein/creatinine (uPCR) ratios in spot urine samples can be used to evaluate albuminuria and proteinuria in hereditary transthyretin amyloidosis patients.
Alzheimer Disease
A highly sensitive fluorescent probe that quantifies transthyretin in human plasma as an early diagnostic tool of Alzheimer's disease.
A Mutation in NPAS3 That Segregates with Schizophrenia in a Small Family Leads to Protein Aggregation.
A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition.
Accurate, strong, and stable reporting of choroid plexus epithelial cells in transgenic mice using a human transthyretin BAC.
An aberrant protein complex in CSF as a biomarker of Alzheimer disease.
Analyses of transthyretin concentration in the cerebrospinal fluid of patients with Guillain-Barré syndrome and other neurological disorders.
Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry.
Association of TTR polymorphisms with hippocampal atrophy in Alzheimer disease families.
Asymmetric expression patterns of brain transthyretin in normal mice and a transgenic mouse model of Alzheimer's disease.
Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis.
Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease.
Copper mediated amyloid-? binding to Transthyretin.
Crystal and molecular structure of piceatannol; scavenging features of resveratrol and piceatannol on hydroxyl and peroxyl radicals and docking with transthyretin.
Differential post-translational modifications of transthyretin in Alzheimer's disease: A study of the cerebral spinal fluid.
Distinct transthyretin oxidation isoform profile in spinal fluid from patients with Alzheimer's disease and mild cognitive impairment.
Effect of Red Wine Polyphenols on the Expression of Transthyretin in Murine Choroid Plexus.
Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study.
Elevated risks for amyotrophic lateral sclerosis and blood disorders in Ashkenazi schizophrenic pedigrees suggest new candidate genes in schizophrenia.
Evidence for synergistic action of transthyretin and IGF-I over the IGF-I receptor.
Fluorescence as a method to reveal structures and membrane-interactions of amyloidogenic proteins.
Gender-Dependent Transthyretin Modulation of Brain Amyloid-? Levels: Evidence from a Mouse Model of Alzheimer's Disease.
Human Serum Transthyretin Levels Correlate Inversely with Alzheimer's Disease.
Immunoglobulin light chains, glycosaminoglycans, and amyloid.
Increased protein glycation in cerebrospinal fluid of Alzheimer's disease.
Isolated atrial amyloidosis and the importance of molecular classification.
Mechanisms of transthyretin inhibition of ?-amyloid aggregation in vitro.
Mitochondria-targeted catalase reduces abnormal APP processing, amyloid ? production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension.
Molecular biology of brain aging and neurodegenerative disorders.
Neuronal production of transthyretin in human and murine Alzheimer's disease: is it protective?
Nucleobindin 1 binds to multiple types of pre-fibrillar amyloid and inhibits fibrillization.
Plasma transthyretin as a candidate marker for Alzheimer's disease.
Possible involvement of transthyretin in hippocampal beta-amyloid burden and learning behaviors in a mouse model of Alzheimer's disease (TgCRND8).
Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia.
Radiofrequency Fields, Transthyretin, and Alzheimer's Disease.
Rare Genetic Variants of the Transthyretin Gene Are Associated with Alzheimer's Disease in Han Chinese.
Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia.
Serum levels of proteins involved in amyloid-? clearance are related to cognitive decline and neuroimaging changes in mild cognitive impairment.
Stability of the transthyretin molecule as a key factor in the interaction with a-beta peptide--relevance in Alzheimer's disease.
Sustained choroid plexus function in human elderly and Alzheimer's disease patients.
Targeted Nuclear Imaging Probes for Cardiac Amyloidosis.
The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-beta (A beta) 40, A beta 4242, apolipoprotein E and transthyretin in human cerebrospinal fluid.
The protease activity of transthyretin reverses the effect of pH on the amyloid-? protein/heparan sulfate proteoglycan interaction: a biochromatographic study.
The systemic amyloid precursor transthyretin (TTR) behaves as a neuronal stress protein regulated by HSF1 in SH-SY5Y human neuroblastoma cells and APP23 Alzheimer's disease model mice.
Transthyretin accelerates vascular Abeta deposition in a mouse model of Alzheimer's disease.
Transthyretin and Alzheimer's disease: where in the brain?
Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease?
Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors.
Transthyretin binding to A-Beta peptide - Impact on A-Beta fibrillogenesis and toxicity.
Transthyretin gene in Alzheimer's disease patients.
Transthyretin inhibition of amyloid beta aggregation and toxicity.
Transthyretin neuroprotection in Alzheimer's disease is dependent on proteolysis.
Transthyretin stability is critical in assisting beta amyloid clearance- Relevance of transthyretin stabilization in Alzheimer's disease.
Transthyretin stabilization by iododiflunisal promotes amyloid-? peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer's disease mouse model.
[Identification of transthyretin posttranslational modifications 1n human blood using mass-spectrometric methods].
[Transthyretin levels in serum and cerebrospinal fluid sustain the nutrio-viral hypothesis of the Cuban epidemic neuropathy]
Amyloid Neuropathies
A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy.
A novel transthyretin mutation V32A in a Chinese man with late-onset amyloid polyneuropathy.
Amyloid and peripheral nervous system disease.
Amyloid Neuropathy with Transthyretin Mutations: Overview and Unique Ala97Ser in Taiwan.
Amyloid Polyneuropathy and Myocardial Amyloidosis 10 Years after Domino Liver Transplantation from a Patient with a Transthyretin Ser50Arg Mutation.
Amyloid Polyneuropathy Caused By Wild-Type Transthyretin.
Amyloid polyneuropathy in two German-American families: a new transthyretin variant (Val 107).
Amyloid polyneuropathy with transthyretin Arg50 in a Japanese case from Osaka.
An amyotrophic lateral sclerosis-like syndrome revealing an amyloid polyneuropathy associated with a novel transthyretin mutation.
Applying an artificial neural network model for developing a severity score for patients with hereditary amyloid polyneuropathy.
Autonomic dysfunction in peripheral nerve disease.
C1q ablation exacerbates amyloid deposition: A study in a transgenic mouse model of ATTRV30M amyloid neuropathy.
Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant.
Clinical presentations and skin denervation in amyloid neuropathy due to transthyretin Ala97Ser.
Coexistence of familial transthyretin amyloidosis ATTR Val30Met and spinocerebellar ataxia type 1 in a Japanese family--a follow-up autopsy report.
Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid.
Cutaneous Manifestations of Familial Transthyretin Amyloid Polyneuropathy.
Diagnosis of amyloid neuropathy.
Diagnosis of small fiber neuropathy: A comparative study of five neurophysiological tests.
Diflunisal compassive use in transthyretin hereditary amyloid polyneuropathy: report of a first Spanish experience.
Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.
Early skin denervation in hereditary and iatrogenic transthyretin amyloid neuropathy.
Endoplasmic reticulum stress associated with extracellular aggregates. Evidence from transthyretin deposition in familial amyloid polyneuropathy.
Epidemiological and clinical characteristics of persons with transthyretin hereditary amyloid polyneuropathy: a global synthesis of 532 cases.
Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series.
Expression of a synthetic gene encoding human transthyretin in Escherichia coli.
Familial amyloid polyneuropathy: alanine-for-threonine substitution in the transthyretin (prealbumin) molecule.
Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families.
Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France.
Global epidemiology of transthyretin hereditary amyloid polyneuropathy: a systematic review.
Hard to swallow: atypical transthyretin amyloid neuropathy mistaken for CIDP.
Hereditary amyloid neuropathy by transthyretin Val107 mutation in a patient of African origin.
Hereditary neuropathies: An update.
Historical overview of analytical methods for the measurement of transthyretin.
Iatrogenic amyloid polyneuropathy after domino liver transplantation.
Identification of a new transthyretin variant (Ile49) in familial amyloidotic polyneuropathy using electrospray ionization mass spectrometry and nonisotopic RNase cleavage assay.
Immunoassay for transthyretin variants associated with amyloid neuropathy.
Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy.
Late-onset Transthyretin (TTR)-familial Amyloid Polyneuropathy (FAP) with a Long Disease Duration from Non-endemic Areas in Japan.
Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years.
Low erythropoietin production in familial amyloidosis TTR V30M is not related with renal congophilic amyloid deposition. A clinicopathologic study of twelve cases.
Metabolic turn over of amyloid fibrils and post-treatment regression of amyloid deposits in systemic amyloidosis with polyneuropathy.
Molecular genetics of peripheral neuropathies.
Neurophysiological techniques to detect early small-fiber dysfunction in transthyretin amyloid polyneuropathy.
New structural information and update on liver transplantation in transthyretin-associated amyloidosis. Report from the 4th International Symposium on Familial Amyloidotic Polyneuropathy and Other Transthyretin Related Disorders & the 3rd International Workshop on Liver Transplantation in Familial Amyloid Polyneuropathy, Umeå Sweden, June 1999.
New transthyretin mutation V28M in a Portuguese kindred with amyloid polyneuropathy.
Parent-of-origin effect in transthyretin related amyloid polyneuropathy.
Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy.
PEL: an unbiased method for estimating age-dependent genetic disease risk from pedigree data unselected for family history.
Phenotypes of Late-Onset Transthyretin Amyloid Neuropathy: A Diagnostic Challenge.
Poor outcome after liver transplantation for transthyretin amyloid neuropathy in a family with an Ala36Pro transthyretin mutation: case report.
Progression of transthyretin amyloid neuropathy after liver transplantation.
Quantified sensory abnormalities in early genetically verified transthyretin amyloid polyneuropathy.
Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy.
Rapidly progressive amyloid polyneuropathy associated with a novel variant transthyretin serine 25.
Refine penetrance estimates in the main pathogenic variants of transthyretin hereditary (familial) amyloid polyneuropathy (TTR-FAP) using a new non-parametric approach (NPSE).
Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials.
Sudomotor innervation in transthyretin amyloid neuropathy: Pathology and functional correlates.
Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease.
Systemic amyloidosis in laying Japanese quail.
Tafamidis for a Transplant Patient with Transthyretin Amyloid Polyneuropathy.
The clinical and biochemical spectrum of hereditary amyloidosis.
The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients.
Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox?
Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy.
Transthyretin amyloidosis presenting with multifocal demyelinating mononeuropathies.
Transthyretin gene mutations in British and French patients with amyloid neuropathy.
Transthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy.
Transthyretin Val 107 in a Japanese patient with familial amyloid polyneuropathy.
Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials.
[Aged onset of amyloidosis caused by transthyretin gene mutations]
[Amyloid neuropathy resulting from an unknown protein.]
[Amyloidoses].
[Autonomic peripheral neuropathy].
[Ocular involvement in familial amyloid polyneuropathy].
[Transthyretin familial amyloid polyneuropathy].
Amyloid Neuropathies, Familial
"Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy.
1H-NMR structural studies of a cystine-linked peptide containing residues 71-93 of transthyretin and effects of a Ser84 substitution implicated in familial amyloidotic polyneuropathy.
A case of familial amyloid polyneuropathy (FAP ATTR Ile107Val) with proximal muscle weakness in the lower extremities.
A case of familial amyloid polyneuropathy due to Phe33Val TTR with vitreous involvement as the initial manifestation.
A case of familial amyloid polyneuropathy homozygous for the transthyretin Val30Met gene with motor-dominant sensorimotor polyneuropathy and unusual sural nerve pathological findings.
A case of hereditary amyloidosis transthyretin variant Met 30 with amyloid cardiomyopathy, less polyneuropathy, and the presence of giant cells.
A European family with histidine 58 transthyretin mutation in familial amyloid polyneuropathy.
A homozygote case of familial amyloid polyneuropathy amyloidgenic transthyretin Val30Met in a non-endemic area.
A look into amyloid formation by transthyretin: aggregation pathway and a novel kinetic model.
A Missense Variant p.Ala117Ser in the Transthyretin Gene of a Han Chinese Family with Familial Amyloid Polyneuropathy.
A new mutant transthyretin (Arg 10) associated with familial amyloid polyneuropathy.
A new prion disease: relationship with central and peripheral amyloidoses.
A new transthyretin variant (Ser 24) associated with familial amyloid polyneuropathy.
A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred.
A peripheral pathway to restless legs syndrome? Clues from familial amyloid polyneuropathy.
A prospective, observational study of patients with uncommon distal symmetric painful small-fiber neuropathy.
A selective transthyretin-adsorption column for the treatment of patients with familial amyloid polyneuropathy.
A woman with a rare p.Glu74Gly transthyretin mutation presenting exclusively with a rapidly progressive neuropathy: a case report.
ABO-incompatible auxiliary partial orthotopic liver transplant for late-onset familial amyloid polyneuropathy.
Ala97Ser mutation is common among ethnic Chinese Malaysians with transthyretin familial amyloid polyneuropathy.
Alanine-to-threonine substitutions and amyloid diseases: Butyrylcholinesterase as a case study.
Ambulatory Medicines Cost With Transthyretin Familial Amyloid Polyneuropathy In Portugal.
Amyloid fibril protein in familial amyloidosis with cranial neuropathy and corneal lattice dystrophy (FAP type IV) is related to transthyretin.
Amyloidogenic transthyretin Val30Met homozygote showing unusually early-onset familial amyloid polyneuropathy.
An aggressive form of familial amyloid polyneuropathy caused by a Glu54Gly mutation in the transthyretin gene.
An Isolated Case of Late-onset Amyloidogenic Transthyretin Type Familial Amyloid Polyneuropathy Associated with a Mutant Transthyretin Substituting Methionine for Valine at Position 30 Showing Latent Progressive Cardiac Involvement Confirmed by Serial Annual Electrocardiograms.
Annual electrocardiograms consistent with silent progression of cardiac involvement in sporadic familial amyloid polyneuropathy: a case report.
Arrhythmia--a pitfall in tests of cardiac autonomic function after liver transplantation for familial amyloidotic polyneuropathy: a long-term follow-up of Swedish patients.
Assessment of autonomic innervation of the foot in familial amyloid polyneuropathy.
Asymptomatic homozygous gene carrier in a family with type I familial amyloid polyneuropathy.
Author response: Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy.
Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis).
Autosomal-dominant transthyretin (TTR)-related amyloidosis is not a frequent CMT2 neuropathy "in disguise".
Baseline disease characteristics in Brazilian patients enrolled in Transthyretin Amyloidosis Outcome Survey (THAOS).
Binding and stabilization of transthyretin by curcumin.
Biophysical characterization and modulation of Transthyretin Ala97Ser.
Birth of two healthy females after preimplantation genetic diagnosis for familial amyloid polyneuropathy.
Brazilian consensus for diagnosis, management and treatment of transthyretin familial amyloid polyneuropathy.
C1QA and C1QC modify age-at-onset in familial amyloid polyneuropathy patients.
Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin.
Cardiac and peripheral vasomotor autonomic functions in late-onset transthyretin Val30Met familial amyloid polyneuropathy.
Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant.
Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability.
Cause of death analysis and temporal trends in survival after liver transplantation for transthyretin familial amyloid polyneuropathy.
Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantation.
Characterisation and management of vitreous and nerve amyloid in familial amyloid polyneuropathy due to variant transthyretin, Phe33Val.
Characterization of a transthyretin-related amyloid fibril protein from cerebral amyloid angiopathy in type I familial amyloid polyneuropathy.
Characterization of Pain in Familial Amyloid Polyneuropathy.
Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers.
Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein AI Gly26Arg.
Clinical and genetic findings in eight Israeli patients with transthyretin-associated familial amyloid polyneuropathy.
Clinical and pathological findings in familial amyloid polyneuropathy caused by a transthyretin E61K mutation.
Clinical and pathological studies of cardiac amyloidosis in transthyretin type familial amyloid polyneuropathy.
Clinical features of familial amyloid polyneuropathy carrying transthyretin mutations in four Chinese kindreds.
Clinical features of TTR-FAP in Portugal.
Clinical measures in transthyretin familial amyloid polyneuropathy.
Clinical presentations and skin denervation in amyloid neuropathy due to transthyretin Ala97Ser.
Coexistence of transthyretin familial amyloid polyneuropathy and hereditary neuropathy with liability to pressure palsy.
Comparison Between 99mTc-Diphosphonate Imaging and MRI With Late Gadolinium Enhancement in Evaluating Cardiac Involvement in Patients With Transthyretin Familial Amyloid Polyneuropathy.
Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
Contributions of Animal Models to the Mechanisms and Therapies of Transthyretin Amyloidosis.
Correction to: Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.
Curcumin could reduce the monomer of TTR with Tyr114Cys mutation via autophagy in cell model of familial amyloid polyneuropathy.
Current and Future Treatment Approaches in Transthyretin Familial Amyloid Polyneuropathy.
Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy.
Deposition and passage of transthyretin through the blood-nerve barrier in recipients of familial amyloid polyneuropathy livers.
Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening.
Diagnosis and management of sensory polyneuropathy.
Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.
Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis.
Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy.
Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP).
Diffuse metabolic changes in the brain of patients with familial amyloid polyneuropathy. A proton MRSI study.
Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis.
Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities.
Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy.
Domino liver transplantation: a practical option in the face of the organ shortage.
Early detection of sympathetic myocardial denervation in patients with familial amyloid polyneuropathy type I.
Early diagnosis in patients with transthyretin familial amyloid polyneuropathy: A comparative study.
Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.
Editors' note: Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy.
Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy.
Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Varl30Met: A phase III, open-label study.
Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal animal model.
Electromyographic findings in transthyretin (TTR)-related familial amyloid polyneuropathy (FAP).
Electrophysiological features of familial amyloid polyneuropathy in endemic area.
Electrophysiological features of late-onset transthyretin Met30 familial amyloid polyneuropathy unrelated to endemic foci.
Endoplasmic reticulum stress associated with extracellular aggregates. Evidence from transthyretin deposition in familial amyloid polyneuropathy.
Endoscopic Findings of Small-Bowel Lesions in Familial Amyloid Polyneuropathy: A Case Report.
Epidemiology of Transthyretin Familial Amyloid Polyneuropathy in Portugal: A Nationwide Study.
Epidemiology of transthyretin-associated familial amyloid polyneuropathy in the Majorcan area: Son Llàtzer Hospital descriptive study.
Estimating the global prevalence of transthyretin familial amyloid polyneuropathy.
Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma.
Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like Cells.
Extended phenotype in the transthyretin Tyr77 familial amyloid polyneuropathy.
Extremely Early Onset Transthyretin Familial Amyloid Polyneuropathy with a Leu55Pro Mutation: A Pediatric Case Report and Literature Review.
Familial amyloid polyneuropathy associated with the novel transthyretin variant Arg34Gly.
Familial amyloid polyneuropathy associated with the transthyretin Cys114 gene in a Japanese kindred.
Familial amyloid polyneuropathy associated with transthyretin Gly42 mutation: a quantitative light and electron microscopic study of the peripheral nervous system.
Familial amyloid polyneuropathy in a Spanish family with a transthyretin deletion (deltaVal 122) presenting with carpal tunnel syndrome.
Familial amyloid polyneuropathy in Taiwan: identification of transthyretin variant (Leu55-->Pro).
Familial amyloid polyneuropathy involving a homozygous Val30Met mutation in the amyloidogenic transthyretin gene presenting with superficial siderosis: a case report.
Familial amyloid polyneuropathy related to transthyretin Gly42 in a Japanese family.
Familial amyloid polyneuropathy related to transthyretin mutation Val30 to Leu in a Japanese family.
Familial amyloid polyneuropathy type I (Portuguese): distribution and characterization of renal amyloid deposits.
Familial amyloid polyneuropathy with chronic paroxysmal dry cough in Mainland China: A Chinese family with a proven heterozygous missense mutation c.349G>T in the transthyretin gene.
Familial amyloid polyneuropathy with genetic anticipation associated to a gly47glu transthyretin variant in an Italian kindred.
Familial amyloid polyneuropathy.
Familial Amyloid Polyneuropathy.
Familial amyloid polyneuropathy: a clinico-pathologic study.
Familial amyloid polyneuropathy: alanine-for-threonine substitution in the transthyretin (prealbumin) molecule.
Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways.
Familial amyloid polyneuropathy: When does it stop to be asymptomatic and need a treatment?
Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis.
Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy.
FAP neuropathy and emerging treatments.
First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy.
FRET studies of various conformational states adopted by transthyretin.
Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis.
Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France.
Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTR-FAP) in Turkey.
Haplotypes and DNA sequence variation within and surrounding the transthyretin gene: genotype-phenotype correlations in familial amyloid polyneuropathy (V30M) in Portugal and Sweden.
Health-Related Quality of Life In Patients With Transthyretin Familial Amyloid Polyneuropathy.
Hepatocyte-like cells reveal novel role of SERPINA1 in transthyretin amyloidosis.
Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population.
High hydrostatic pressure dissociates early aggregates of TTR105-115, but not the mature amyloid fibrils.
Hsf-1 affects podocyte markers NPHS1, NPHS2 and WT1 in a transgenic mouse model of TTRVal30Met-related amyloidosis.
Immunostaining images of vitreous transthyretin amyloid.
Impact of liver transplantation on cardiac autonomic denervation in familial amyloid polyneuropathy.
In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography.
Ineffectiveness of dialysis in transthyretin (TTR) clearance in familial amyloid polyneuropathy type I, in spite of lower stability of the TTR Met30 variant.
Inflammatory profiling of patients with familial amyloid polyneuropathy.
Inflammatory state exists in familial amyloid polyneuropathy that may be triggered by mutated transthyretin.
Inhibiting transthyretin amyloid fibril formation via protein stabilization.
Inhibition of human transthyretin aggregation by non-steroidal anti-inflammatory compounds: a structural and thermodynamic analysis.
Inhibitory activities of propolis and its promising component, caffeic acid phenethyl ester, against amyloidogenesis of human transthyretin.
Involvement of Macrophages in the Pathogenesis of Familial Amyloid Polyneuropathy and Efficacy of Human iPS Cell-Derived Macrophages in Its Treatment.
Kidney and anemia in familial amyloidosis type I.
Large normal alleles of ATXN2 decrease age at onset in transthyretin familial amyloid polyneuropathy Val30Met patients.
Late-onset and fast progressive neuropathy and cardiomyopathy in Val32Ala transthyretin gene mutation.
Late-onset familial amyloid polyneuropathy (FAP) Val30Met without family history.
Late-onset familial amyloid polyneuropathy in Japan.
Late-onset familial amyloid polyneuropathy: an autopsy study of two Japanese brothers.
Late-onset Transthyretin (TTR)-familial Amyloid Polyneuropathy (FAP) with a Long Disease Duration from Non-endemic Areas in Japan.
Liver transplantation and anemia in familial amyloidosis ATTR V30M.
Liver transplantation as treatment for neurological disorders.
Liver transplantation in transthyretin familial amyloid polyneuropathy: first report from Argentina.
Liver transplantation in transthyretin-related familial amyloid polyneuropathy.
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.
Long-term follow-up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type).
Long-term quantitative evaluation of liver transplantation in familial amyloid polyneuropathy (Portuguese V30M).
Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy.
Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study.
Lower kinetic limit to protein thermal stability: a proposal regarding protein stability in vivo and its relation with misfolding diseases.
Macular and optic disc edema and retinal vascular leakage in familial amyloid polyneuropathy with a transthyretin Val30Met mutation: a case report.
Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy.
Modifications of the 7-Hydroxyl Group of the Transthyretin Ligand Luteolin Provide Mechanistic Insights into Its Binding Properties and High Plasma Specificity.
Modulating conformational factors in transthyretin amyloid.
Molecular genetics of amyloid neuropathy in Europe.
MRI of cardiac involvement in transthyretin familial amyloid polyneuropathy.
Multimodal retinal imaging in a Chinese kindred with familial amyloid polyneuropathy secondary to transthyretin Ile107Met mutation.
Muscular amyloid angiopathy with amyloidgenic transthyretin Ser50Ile and Tyr114Cys.
Myopathic phenotype of familial amyloid polyneuropathy with a rare transthyretin variant: ATTR Ala45Asp.
Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy.
Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas.
Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling.
Neurophysiological markers of small fibre neuropathy in TTR-FAP mutation carriers.
Neurophysiological techniques to detect early small-fiber dysfunction in transthyretin amyloid polyneuropathy.
New structural information and update on liver transplantation in transthyretin-associated amyloidosis. Report from the 4th International Symposium on Familial Amyloidotic Polyneuropathy and Other Transthyretin Related Disorders & the 3rd International Workshop on Liver Transplantation in Familial Amyloid Polyneuropathy, Umeå Sweden, June 1999.
Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy.
Nucleobindin 1 binds to multiple types of pre-fibrillar amyloid and inhibits fibrillization.
Occupational and other risk factors for clinically overt familial amyloid polyneuropathy.
Ocular amyloidosis and secondary glaucoma.
On the origin of the transthyretin Val30Met familial amyloid polyneuropathy.
Ophthalmic manifestations in a Chinese family with familial amyloid polyneuropathy due to a TTR Gly83Arg mutation.
Optimizing the management of transthyretin familial amyloid polyneuropathy in Europe: early diagnosis and effective care.
Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan.
Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy.
Pathology and functional diagnosis of small-fiber painful neuropathy.
Penetrance estimation of TTR familial amyloid polyneuropathy (type I) in Brazilian families.
Phenotypic expression of familial amyloid polyneuropathy in Brazil.
Phenotypic heterogeneity in a family with FAP due to a TTR Leu58Arg mutation: a clinicopathologic study.
Polymer-doxycycline conjugates as fibril disrupters: an approach towards the treatment of a rare amyloidotic disease.
Portuguese-type amyloidosis (transthyretin amyloidosis, ATTR V30M).
Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis.
Postmortem findings in a familial amyloid polyneuropathy patient with homozygosity of the mutant Val30Met transthyretin gene.
Potential Role of In Vivo Confocal Microscopy for Imaging Corneal Nerves in Transthyretin Familial Amyloid Polyneuropathy.
Presence of N-glycosylated transthyretin in plasma of V30M carriers in familial amyloidotic polyneuropathy: an escape from ERAD.
Prevalence of Transthyretin Familial Amyloid Polyneuropathy In Portugal.
Progression of myocardial sympathetic denervation assessed by (123)I-MIBG imaging in familial amyloid polyneuropathy and the effect of liver transplantation.
Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation-a prospective single-center cohort study.
Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis.
Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients.
Rapid detection of wild-type and mutated transthyretins.
Rational design of potent human transthyretin amyloid disease inhibitors.
Reader response: Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy.
Recent advances in familial amyloid polyneuropathy.
Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis.
Recurrent syncope as persistently isolated feature of transthyretin amyloidotic polyneuropathy.
Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy.
Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.
Results of liver transplantation for familial amyloid polyneuropathy type I in Brazil.
Retrospective Mapping of SAR Data for TTR Protein in Chemico-Biological Space Using Ligand Efficiency Indices as a Guide to Drug Discovery Strategies.
Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation.
S-sulfonation of transthyretin is an important trigger step in the formation of transthyretin-related amyloid fibril.
Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy.
Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
Sensory nerve degeneration in a mouse model mimicking early manifestations of familial amyloid polyneuropathy due to transthyretin Ala97Ser.
Sequential (domino) transplantation of the liver in a transthyretin-50 familial amyloid polyneuropathy. Special reference to cardiological diagnosis and complications.
Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation.
Serum transthyretin monomer in patients with familial amyloid polyneuropathy.
Severe amyloid deposition in mammary glands of familial amyloid polyneuropathy patients.
Severe heart disease in an unusual case of familial amyloid polyneuropathy type I.
Single-centre experience on transthyretin familial amyloid polyneuropathy: case series and literature review.
Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP.
Skin Nerve Pathology: Biomarkers of Premanifest and Manifest Amyloid Neuropathy.
Somatostatin analogues for refractory diarrhoea in familial amyloid polyneuropathy.
Spinal cord stimulation markedly ameliorated refractory neuropathic pain in transthyretin Val30Met familial amyloid polyneuropathy.
Structural stabilization of transthyretin by a new compound, 6-benzoyl-2-hydroxy-1H-benzo[de]isoquinoline-1,3(2H)-dione.
Sudomotor innervation in transthyretin amyloid neuropathy: Pathology and functional correlates.
Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro.
Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools.
Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease.
Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
Synthesis and structural analysis of halogen substituted fibril formation inhibitors of Human Transthyretin (TTR).
Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial.
Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy.
Tafamidis for transthyretin amyloidosis.
Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial.
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
Tafamidis, a Noninvasive Therapy for Delaying Transthyretin Familial Amyloid Polyneuropathy: Systematic Review and Meta-Analysis.
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
Tafamidis: a review of its use in familial amyloid polyneuropathy.
The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation.
The crystal structure of the green tea polyphenol (-)-epigallocatechin gallate-transthyretin complex reveals a novel binding site distinct from the thyroxine binding site.
The diagnostic accuracy of Sudoscan in transthyretin familial amyloid polyneuropathy.
The diagnostic utility of neurophysiologic tests for early diagnostic of transthyretin familial amyloid polyneuropathy.
The effect of tafamidis on the QTC interval in healthy subjects.
The Endoplasmic Reticulum-associated Degradation of Transthyretin Variants Is Negatively Regulated by BiP in Mammalian Cells.
The first Transthyretin Familial Amyloid Polyneuropathy gait quantification study - preliminary results.
The identification of a transthyretin variant p.D38G in a Chinese family with early-onset leptomeningeal amyloidosis.
The importance of a gatekeeper residue on the aggregation of transthyretin: implications for transthyretin-related amyloidoses.
The pathological and biochemical identification of possible seed-lesions of transmitted transthyretin amyloidosis after domino liver transplantation.
The polyphenol Oleuropein aglycone hinders the growth of toxic transthyretin amyloid assemblies.
The significance of carpal tunnel syndrome in transthyretin Val30Met familial amyloid polyneuropathy.
The Temporal Profiles of Changes in Nerve Excitability Indices in Familial Amyloid Polyneuropathy.
The value of electrochemical skin conductance measurement using Sudoscan® in the assessment of patients with familial amyloid polyneuropathy.
Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis.
Three Turkish families with different transthyretin mutations.
Tongue atrophy and fasciculations in transthyretin familial amyloid neuropathy: An ALS mimicker.
Toward the discovery of functional transthyretin amyloid inhibitors: application of virtual screening methods.
Transthyretin Ala97Ser in Chinese-Taiwanese patients with familial amyloid polyneuropathy: genetic studies and phenotype expression.
Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy.
Transthyretin chemical chaperoning by flavonoids: Structure-activity insights towards the design of potent amyloidosis inhibitors.
Transthyretin enhances nerve regeneration.
Transthyretin familial amyloid polyneuropathy (TTR-FAP) in Mallorca: A comparison between late- and early-onset disease.
Transthyretin familial amyloid polyneuropathy (TTR-FAP): Parameters for early diagnosis.
Transthyretin familial amyloid polyneuropathy due to lle107Val mutation mimicking atypical chronic inflammatory demyelinating polyneuropathy: case report.
Transthyretin Familial Amyloid Polyneuropathy Impact on Health-Related Quality of Life.
Transthyretin familial amyloid polyneuropathy.
Transthyretin familial amyloid polyneuropathy: an update.
Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy.
Transthyretin gene mutations in British and French patients with amyloid neuropathy.
Transthyretin Ile84Thr is associated with familial amyloid polyneuropathy.
Transthyretin internalization by sensory neurons is megalin mediated and necessary for its neuritogenic activity.
Transthyretin is up-regulated by sex hormones in mice liver.
Transthyretin mutation (serine 84) associated with familial amyloid polyneuropathy in a Hungarian family.
Transthyretin mutation (TTRGly47Ala) associated with familial amyloid polyneuropathy in a French family.
Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity.
Transthyretin related familial amyloid polyneuropathy.
Transthyretin Tyr77 familial amyloid polyneuropathy: a clinicopathological study of a large kindred.
Transthyretin Val 107 in a Japanese patient with familial amyloid polyneuropathy.
Transthyretin Val30Met familial amyloid polyneuropathy: a considerably different clinical picture and natural course in endemic and non-endemic areas.
Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area.
Treatment of amyloidosis.
Treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a case report.
Trigger finger as an initial manifestation of familial amyloid polyneuropathy in a patient with Ile107Val TTR.
TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance?
TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies.
TTR-familial amyloid polyneuropathy--neurological aspects.
TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients.
Twenty Years of a Pre-Symptomatic Testing Protocol for Late-Onset Neurological Diseases in Portugal.
Two cases of late onset familial amyloid polyneuropathy with a Glu61Lys transthyretin variant.
Type I familial amyloid polyneuropathy. A pathological study of the peripheral nervous system.
Ultrasound evaluation in transthyretin-related amyloid neuropathy.
Unwanted road to anaemia in transthyretin familial amyloid polyneuropathy may continue irrespective of tafamidis treatment.
Up-regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinase-associated lipocalin, and matrix metalloproteinase-9 in familial amyloid polyneuropathy.
Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy.
Upper limb neuropathy such as carpal tunnel syndrome as an initial manifestation of ATTR Val30Met familial amyloid polyneuropathy.
Usefulness of combined nerve and muscle biopsy in the diagnosis of amyloid neuropathy--a study of 6 new cases.
Usefulness of MALDI/TOF mass spectrometry of immunoprecipitated serum variant transthyretin in the diagnosis of familial amyloid polyneuropathy.
Variants in RBP4 and AR genes modulate age at onset in familial amyloid polyneuropathy (FAP ATTRV30M).
Vitreous amyloidosis after liver transplantation in patients with familial amyloid polyneuropathy: ocular synthesis of mutant transthyretin.
Vitreous Amyloidosis: Ocular, Systemic, and Genetic Insights.
Widespread Cardiac and Vasomotor Autonomic Dysfunction in Non-Val30Met Hereditary Transthyretin Amyloidosis.
Wild-type transthyretin significantly contributes to the formation of amyloid fibrils in familial amyloid polyneuropathy patients with amyloidogenic transthyretin Val30Met.
[Aged onset of amyloidosis caused by transthyretin gene mutations]
[Case report of transthyretin Val30Met familial amyloid polyneuropathy presenting hydrocephalus].
[Clinical and genetic heterogeneity in familial amyloidotic polyneuropathy associated with variant transthyretin]
[Demonstration of genetic mutation in most of the amyloid neuropathies with sporadic occurrence]
[Diagnosis of familial amyloid polyneuropathy type I in Argentina]
[Familial amyloid neuropathy associated with the Cys114 mutation of the transthyretin gene in a Russian family]
[Familial amyloid polyneuropathy: liver transplantation as first-line therapy].
[Familial amyloid polyneuropathy].
[Familial amyloidotic polyneuropathies].
[Genetic analysis and a new therapy for a hereditary disease: familial amyloid polyneuropathy]
[Identification of transthyretin posttranslational modifications 1n human blood using mass-spectrometric methods].
[Liver transplantation in familial amyloid polyneuropathy. Case report and review of the literature]
[Ocular involvement in familial amyloid polyneuropathy].
[Perioperative management for liver transplant in a patient with familial amyloid polyneuropathy with heart involvement.]
[Presentations of transthyretin associated familial amyloid polyneuropathy in Argentina].
[The ocular involvement in the transthyretin-related familial amyloid polyneuropathy].
[Transthyretin and familial amyloid polyneuropathies]
[Transthyretin familial amyloid polyneuropathy - three Hungarian cases with rare mutations (His88Arg and Phe33Leu)].
[Variant transthyretin genes associated with familial amyloid polyneuropathy]
[What's new in hereditary neuropathies ?].
Amyloidosis
(99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis.
(99m)Tc-HMDP scintigraphy rectifies wrong diagnosis of AL amyloidosis.
18F-Florbetaben: A New Tool for Amyloidosis Staging?
18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study.
1H-NMR structural studies of a cystine-linked peptide containing residues 71-93 of transthyretin and effects of a Ser84 substitution implicated in familial amyloidotic polyneuropathy.
6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR).
99mTc DPD is the preferential bone tracer for diagnosis of cardiac transthyretin amyloidosis.
99mTechnetium pyrophosphate scintigraphy with cadmium zinc telluride cameras is a highly sensitive and specific imaging modality to diagnose transthyretin cardiac amyloidosis.
?-Synuclein aggregation in the saliva of familial transthyretin amyloidosis: a potential biomarker.
A case of a senile systemic amyloidosis patient presenting with angina pectoris and dilated cardiomyopathy.
A case of biopsy-proven leptomeningeal amyloidosis and intravenous Ig-responsive polyneuropathy associated with the Ala25Thr transthyretin gene mutation.
A case of late onset cardiac amyloidosis with a new transthyretin variant (lysine 92).
A case of transthyretin amyloidosis with myopathy, neuropathy, and cardiomyopathy resulting from an exceedingly rare mutation transthyretin Ala120Ser (c.418G?>?T, p.Ala140Ser).
A case of vitreous amyloidosis without systemic symptoms in familial amyloidotic polyneuropathy.
A case of wild-type transthyretin amyloidosis associated with organizing pneumonia.
A case report of osteoarthritis associated with hereditary transthyretin amyloidosis ATTRV30M.
A case study of likely wild-type cardiac transthyretin amyloidosis causing rapid deterioration.
A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH.
A complex equilibrium among partially unfolded conformations in monomeric transthyretin.
A compound T60A and V122I heterozygosity in the transthyretin gene causing early onset severe cardiac amyloidosis.
A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy.
A current pharmacologic agent versus the promise of next generation therapeutics to ameliorate protein misfolding and/or aggregation diseases.
A deceptive case of amyloid myopathy: clinical and magnetic resonance imaging features.
A Focused Review on the Pathophysiology, Diagnosis, and Management of Cardiac Amyloidosis.
A genealogical and clinical study of the phenotypical variation within the Swedish transthyretin His88Arg (p. His108Arg) amyloidosis family.
A Heart too Stiff to Beat: A Case of Familial Transthyretin Amyloidosis Cardiomyopathy.
A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a late-onset disease of genetic etiology.
A late-onset case of hereditary transthyretin amyloidosis with a novel compound heterozygous mutation.
A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics.
A look into amyloid formation by transthyretin: aggregation pathway and a novel kinetic model.
A molecular correlate of clinicopathology in transthyretin amyloidosis.
A molecular mechanism for transthyretin amyloidogenesis.
A mouse model of a novel missense mutation (Gly83Arg) in a Chinese kindred manifesting vitreous amyloidosis only.
A Mutation in NPAS3 That Segregates with Schizophrenia in a Small Family Leads to Protein Aggregation.
A new amyloidogenic transthyretin variant (Val122Ala) found in a compound heterozygous patient.
A new amyloidogenic transthyretin variant, [D38A], detected by electrospray ionization/mass spectrometry.
A New Arg54Gly Transthyretin Gene Mutation Associated with Vitreous Amyloidosis in Chinese.
A new crystal form of human transthyretin obtained with a curcumin derived ligand.
A new diagnostic procedure to detect unknown transthyretin (TTR) mutations in familial amyloidotic polyneuropathy (FAP).
A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene.
A new isoleucine substitution of Val-20 in transthyretin tetramers selectively impairs dimer-dimer contacts and causes systemic amyloidosis.
A new prion disease: relationship with central and peripheral amyloidoses.
A new simple and rapid screening method for variant transthyretin-related amyloidosis.
A new staging system for cardiac transthyretin amyloidosis.
A new Thr49Pro transthyretin gene mutation associated with leptomeningeal amyloidosis.
A new transthyretin mutation associated with amyloidotic vitreous opacities. Asparagine for isoleucine at position 84.
A new transthyretin mutation associated with leptomeningeal amyloidosis.
A new transthyretin variant Leu55Gln in a patient with systemic amyloidosis.
A novel amyloidogenic transthyretin variant, Gly53Ala, associated with intermittent headaches and ataxia.
A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition.
A novel tool for detecting amyloid deposits in systemic amyloidosis in vitro and in vivo.
A novel transthyretin Lys70Glu (p.Lys90Glu) mutation presenting with vitreous amyloidosis and carpal tunnel syndrome.
A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred.
A novel type of familial transthyretin amyloidosis, ATTR Asn124Ser, with co-localization of kappa light chains.
A novel variant of transthyretin (Glu42Asp) associated with sporadic late-onset cardiac amyloidosis.
A novel variant of transthyretin, 59Thr-->Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family.
A pair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils.
A Patient With Hereditary ATTR and a Novel AGel p.Ala578Pro Amyloidosis.
A practical approach to the diagnosis of systemic amyloidoses.
A rare transthyretin mutation (Asp18Glu) associated with cardiomyopathy.
A rare variant of transthyretin-related amyloidosis associated with exclusive cardiomyopathy in a Hong Kong Chinese patient.
A representative case of hereditary transthyretin amyloidosis complicated by intramyocardial hemorrhage.
A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis.
A review of the amyloidoses that infiltrate the heart.
A simple and reliable method of detecting variant transthyretins by multidimensional liquid chromatography coupled to electrospray ionization mass spectrometry.
A simple screening test for variant transthyretins associated with familial transthyretin amyloidosis using isoelectric focusing.
A specific test for transthyretin 122 (Val----Ile), based on PCR-primer-introduced restriction analysis (PCR-PIRA): confirmation of the gene frequency in blacks.
A sporadic case of late-onset familial amyloid polyneuropathy with a monoclonal gammopathy.
A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK.
A transthyretin mutation (Tyr78Phe) associated with peripheral neuropathy, carpal tunnel syndrome and skin amyloidosis.
Abdominal fat pad excisional biopsy for the diagnosis and typing of systemic amyloidosis.
Abnormal Coronary Flow Velocity Reserve and Decreased Myocardial Contractile Reserve Are Main Factors in Relation to Physical Exercise Capacity in Cardiac Amyloidosis.
Abnormal small bowel motility in patients with hereditary transthyretin amyloidosis.
Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis.
Accurate, strong, and stable reporting of choroid plexus epithelial cells in transgenic mice using a human transthyretin BAC.
Acidic pH-induced conformational changes in amyloidogenic mutant transthyretin.
Acquired transthyretin amyloidosis after domino liver transplant: Phenotypic correlation, implication of liver retransplantation.
Activated microglia mediate synapse loss and short-term memory deficits in a mouse model of transthyretin-related oculoleptomeningeal amyloidosis.
Acute cardiac failure secondary to senile systemic amyloidosis.
Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis.
Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.
Advances in the treatment of hereditary transthyretin amyloidosis: A review.
Advances in Treatment of Cardiac Amyloid.
Affinity capillary electrophoresis is a powerful tool to identify transthyretin binding drugs for potential therapeutic use in amyloidosis.
AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
Age-dependent cognitive dysfunction in untreated hereditary transthyretin amyloidosis.
Age-related oxidative modifications of transthyretin modulate its amyloidogenicity.
Aged vervet monkeys developing transthyretin amyloidosis with the human disease-causing Ile122 allele: a valid pathological model of the human disease.
Ageing and amyloid fibrillogenesis: lessons from apolipoprotein AI, transthyretin and islet amyloid polypeptide.
Aging and transthyretin-related amyloidosis: pathologic examinations in pulmonary amyloidosis.
Albumin/creatinine (uACR) and protein/creatinine (uPCR) ratios in spot urine samples can be used to evaluate albuminuria and proteinuria in hereditary transthyretin amyloidosis patients.
Allele specific expression of the transthyretin gene in swedish patients with hereditary transthyretin amyloidosis (ATTR V30M) is similar between the two alleles.
Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosis.
Amyloid and peripheral nervous system disease.
Amyloid cardiomyopathy in a large integrated health care system.
Amyloid Cardiomyopathy in Hereditary Transthyretin V30M Amyloidosis - Impact of Sex and Amyloid Fibril Composition.
Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology.
Amyloid diseases of the heart: current and future therapies.
Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis.
Amyloid Fibril Composition as a Predictor of Development of Cardiomyopathy After Liver Transplantation for Hereditary Transthyretin Amyloidosis.
Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis.
Amyloid fibril composition within hereditary Val30Met (p. Val50Met) transthyretin amyloidosis families.
Amyloid fibril protein in familial amyloidosis with cranial neuropathy and corneal lattice dystrophy (FAP type IV) is related to transthyretin.
Amyloid localized to tenosynovium at carpal tunnel release. Immunohistochemical identification of amyloid type.
Amyloid PET imaging in cardiac amyloidosis: a pilot study using 18F-flutemetamol positron emission tomography.
Amyloid Polyneuropathy and Myocardial Amyloidosis 10 Years after Domino Liver Transplantation from a Patient with a Transthyretin Ser50Arg Mutation.
Amyloid Polyneuropathy Caused By Wild-Type Transthyretin.
Amyloid polyneuropathy with transthyretin Arg50 in a Japanese case from Osaka.
Amyloid proteins and amyloidoses: complexity updated.
Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.
Amyloid transthyretin cardiac amyloidosis: diagnosis and management.
Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue.
Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage.
Amyloidosis and Unexpected Death: A Review of Seven Cases.
Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types.
Amyloidosis of the gastrointestinal tract: a 13-year single center referral experience.
Amyloidotic breast nodule in hereditary transthyretin amyloidosis (hATTR): a case report.
An aggressive form of transthyretin amyloidosis.
An autopsy case of leptomeningeal amyloidosis associated with transthyretin Gly47Arg mutation.
Analysis of serum transthyretin by on-line immunoaffinity solid-phase extraction capillary electrophoresis mass spectrometry using magnetic beads.
Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience.
Analysis of transthyretin in human serum by capillary zone electrophoresis electrospray ionization time-of-flight mass spectrometry. Application to familial amyloidotic polyneuropathy type I.
Angiographic Signatures of the Predominant Form of Familial Transthyretin Amyloidosis (Val30Met Mutation).
Animal models of human amyloidoses: are transgenic mice worth the time and trouble?
Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy.
Anterior Chamber Flare as an Objective and Quantitative Noninvasive Method for Oculopathy in Transthyretin V30M Amyloidosis Patients.
Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg?
Apical sparing pattern of left ventricular myocardial (99m)Tc-HMDP uptake in patients with transthyretin cardiac amyloidosis.
Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis.
Applications of gene therapy for familial amyloidotic polyneuropathy.
Applying an artificial neural network model for developing a severity score for patients with hereditary amyloid polyneuropathy.
Are cardiomyocytes able to generate pre-amyloid peptides?
Arrhythmia--a pitfall in tests of cardiac autonomic function after liver transplantation for familial amyloidotic polyneuropathy: a long-term follow-up of Swedish patients.
Asp58Ala is the Predominant Mutation of the TTR Gene in Korean Patients with Hereditary Transthyretin-Related Amyloidosis.
Assessment of patients with hereditary transthyretin amyloidosis - understanding the impact of management and disease progression.
Association between a point mutation at the -743-bp region of the transthyretin (TTR) gene and familial vitreous amyloidosis.
Association between hearing loss and hereditary ATTR amyloidosis.
Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis.
Association of Carpal Tunnel Syndrome With Amyloidosis, Heart Failure, and Adverse Cardiovascular Outcomes.
Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study.
Atrial Fibrillation and Central Nervous Complications in Liver Transplanted Hereditary Transthyretin Amyloidosis Patients.
Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality.
Atrial impairment in transthyretin cardiac amyloidosis: an early marker of cardiac involvement and a prognostic factor.
Atypical presentation of transthyretin amyloidosis in a non-endemic area.
Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis).
Autosomal-dominant transthyretin (TTR)-related amyloidosis is not a frequent CMT2 neuropathy "in disguise".
Baseline disease characteristics in Brazilian patients enrolled in Transthyretin Amyloidosis Outcome Survey (THAOS).
Becoming familiar with hereditary transthyretin amyloidosis, a treatable neuropathy.
Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis.
Bifunctional crosslinking ligands for transthyretin.
Binding and stabilization of transthyretin by curcumin.
Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.
Binding site asymmetry in human transthyretin: insights from a joint neutron and X-ray crystallographic analysis using perdeuterated protein.
Biochemical and Electrophysiological Modification of Amyloid Transthyretin on Cardiomyocytes.
Biochemical characteristics of variant transthyretins causing hereditary leptomeningeal amyloidosis.
Biochemical characterization of vitreous and cardiac amyloid in Ile84Ser transthyretin amyloidosis.
Biophysical analysis of normal transthyretin: implications for fibril formation in senile systemic amyloidosis.
Blood-based microRNA profiling in patients with cardiac amyloidosis.
Bone scintigraphy for early detection of transthyretin cardiac amyloidosis.
Burden of hereditary transthyretin amyloidosis on quality of life.
Can echocardiography and ECG discriminate hereditary transthyretin V30M amyloidosis from hypertrophic cardiomyopathy?
Can Nuclear Imaging Techniques Predict Patient Outcome and Guide Medical Management in Hereditary Transthyretin Cardiac Amyloidosis?
Cardiac amyloidosis associated with a novel transthyretin aspartic acid-18 glutamic acid de novo mutation.
Cardiac Amyloidosis Associated With Amyloidogenic Transthyretin V122I Variant in an Elderly Japanese Woman.
Cardiac amyloidosis associated with the transthyretin Ile122 mutation in a Caucasian family.
Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and meta-analysis.
Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis.
Cardiac amyloidosis is associated with increased aortic stiffness.
Cardiac Amyloidosis Phenotype Associated With a Glu89Lys Transthyretin Mutation.
Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation.
Cardiac amyloidosis.
Cardiac amyloidosis: a review and report of a new transthyretin (prealbumin) variant.
Cardiac amyloidosis: An underdiagnosed/underappreciated disease.
Cardiac amyloidosis: An update on diagnosis and treatment.
Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.
Cardiac Amyloidosis: Diagnosis and Treatment Strategies.
Cardiac amyloidosis: evolving approach to diagnosis and management.
Cardiac amyloidosis: heterogenous pathogenic backgrounds.
Cardiac amyloidosis: report of a patient heterozygous for the transthyretin isoleucine 122 variant.
Cardiac amyloidosis: the need for early diagnosis.
Cardiac amyloidosis: Updates in diagnosis and management.
Cardiac Amyloidosis: Updates in Imaging.
Cardiac amyloidosis: where are we today?
Cardiac and peripheral vasomotor autonomic functions in hereditary transthyretin amyloidosis with non-Val30Met mutation.
Cardiac denervation evidenced by MIBG occurs earlier than amyloid deposits detection by diphosphonate scintigraphy in TTR mutation carriers.
Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality.
Cardiac Dysautonomia and Survival in Hereditary Transthyretin Amyloidosis.
Cardiac Dysautonomia Predicts Long-Term Survival in Hereditary Transthyretin Amyloidosis After Liver Transplantation.
Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients with non-Val30Met and non-Val122Ile Hereditary Transthyretin Amyloidosis.
Cardiac involvement after liver transplantation in patients with Val30Met transthyretin amyloidosis from Majorca focus.
Cardiac involvement in a large cohort of patients with Val30Met transthyretin amyloidosis from Majorca focus.
Cardiac Involvement in a Patient Cohort With Val30Met Mutation Transthyretin Amyloidosis.
Cardiac Involvement Secondary to a Familial Form of Transthyretin Amyloidosis Resulting From the Glu54Gln Mutation.
Cardiac manifestations and prognostic implications of hereditary transthyretin amyloidosis associated with transthyretin Ala97Ser.
Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles.
Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability.
Cardiac transthyretin amyloidosis.
Cardiomyopathy in a Japanese family with the Glu61Lys transthyretin variant: a new phenotype.
Cardiovascular autonomic functions in late-onset hereditary transthyretin amyloidosis with Val30Met mutation.
Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?
Carpal tunnel syndrome is associated with high fibrinogen and fibrinogen deposits.
Carpal Tunnel Syndrome: A Potential Early, Red-Flag Sign of Amyloidosis.
Case report of a young patient with transthyretin amyloidosis associated with Gly67Ala mutation.
Catheter Ablation for Atrial Arrhythmias in Patients With Cardiac Amyloidosis.
Cause of death analysis and temporal trends in survival after liver transplantation for transthyretin familial amyloid polyneuropathy.
Causes and Consequences of Longitudinal LV Dysfunction Assessed by 2D Strain Echocardiography in Cardiac Amyloidosis.
Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation.
Cellular clearance of circulating transthyretin decreases cell-nonautonomous proteotoxicity in Caenorhabditis elegans.
Cerebral embolism secondary to cardiac amyloidosis: A case report and literature review.
Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients.
Cervicomedullary compression as the main manifestation of wild-type transthyretin amyloidosis.
Changes in nerve excitability indices in hereditary transthyretin amyloidosis.
Changes in tissue proteome associated with ATTR amyloidosis: insights into pathogenesis.
Characterisation of serum transthyretin by electrospray ionisation-ion mobility mass spectrometry: Application to familial amyloidotic polyneuropathy type I (FAP-I).
Characteristics of acquired transthyretin amyloidosis: A case series and review of the literature.
Characteristics of South Korean Patients with Hereditary Transthyretin Amyloidosis.
Characterization of end-stage renal disease after liver transplantation in transthyretin amyloidosis (ATTR V30M).
Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
Characterization of transthyretin mutants from serum using immunoprecipitation, HPLC/electrospray ionization and matrix-assisted laser desorption/ionization mass spectrometry.
Characterization of transthyretin variants in familial transthyretin amyloidosis by mass spectrometric peptide mapping and DNA sequence analysis.
Characterization of untyped cardiac amyloidosis by mass spectrometry in a patient with Gly6Ser transthyretin polymorphism in fatal cardiogenic shock.
Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers.
Chinese familial transthyretin amyloidosis with vitreous involvement is associated with the transthyretin mutation Gly83Arg: a case report and literature review.
Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation.
Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis.
Clearance of extracellular misfolded proteins in systemic amyloidosis: Experience with transthyretin.
Clinical and echocardiographic characteristics for differentiating between transthyretin-related and light-chain cardiac amyloidoses.
Clinical and genetic profiles of hereditary transthyretin amyloidosis in Taiwan.
Clinical and pathological findings in familial amyloid polyneuropathy caused by a transthyretin E61K mutation.
Clinical and pathological studies of cardiac amyloidosis in transthyretin type familial amyloid polyneuropathy.
Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths.
Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy.
Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics.
Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis.
Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy.
Clinical Images: Carpal tunnel biopsy identifying transthyretin amyloidosis.
Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis.
Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction.
Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology.
Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis.
Clinical symptomatic de novo systemic transthyretin amyloidosis 9 years after domino liver transplantation.
Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy.
Clinicopathological and biochemical findings of late-onset hereditary transthyretin amyloidosis 16 years after liver transplantation: an autopsy case study.
Clinicopathological and biochemical findings of thyroid amyloid in hereditary transthyretin amyloidosis with and without liver transplantation.
Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study.
Clusterin regulates transthyretin amyloidosis.
CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
Codeposition of apolipoprotein A-IV and transthyretin in senile systemic (ATTR) amyloidosis.
Coexistence of familial transthyretin amyloidosis ATTR Val30Met and spinocerebellar ataxia type 1 in a Japanese family--a follow-up autopsy report.
Coexistence of transthyretin- and A?-type cerebral amyloid angiopathy in a patient with hereditary transthyretin V30M amyloidosis.
Coexistent asymptomatic myeloma and hereditary cardiac amyloidosis: an unusual case of heart failure.
Combination of Commonly Examined Parameters Is a Useful Predictor of Positive 99 mTc-Labeled Pyrophosphate Scintigraphy Findings in Elderly Patients With Suspected Transthyretin Cardiac Amyloidosis.
Combined heart and liver transplantation for familial amyloidotic neuropathy.
Common clinicopathological features in late-onset hereditary transthyretin amyloidosis (Ala97Gly, Val94Gly and Val30Met).
Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin.
Comparison of capillary electrophoresis and capillary liquid chromatography coupled to mass spectrometry for the analysis of transthyretin in human serum.
Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center.
Comparison of different types of cardiac amyloidosis by cardiac magnetic resonance imaging.
Comparison of quantitative sensory testing and heart rate variability in Swedish Val30Met ATTR.
Comparison of the standard and speckle tracking echocardiographic features of wild-type and mutated transthyretin cardiac amyloidoses.
Computational studies on transthyretin.
Conjunctival lymphangiectasia: a novel ocular manifestation of hereditary transthyretin amyloidosis.
Considerably Unfolded Transthyretin Monomers Preceed and Exchange with Dynamically Structured Amyloid Protofibrils.
Considering amyloidosis in patients with clinically unresponsive vitreous inflammation (Oculoleptomeningeal amyloidosis in 3 individuals with transthyretin variant Tyr69His. Vol. 44[3]).
Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid.
Contributions of Animal Models to the Mechanisms and Therapies of Transthyretin Amyloidosis.
Correction to: Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.
Corrigendum: Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses.
Cost-effectiveness of technetium pyrophosphate scintigraphy versus heart biopsy for the diagnosis of transthyretin amyloidosis.
Curcumin: A multi-target disease-modifying agent for late-stage transthyretin amyloidosis.
Current and future treatment of amyloid diseases.
Current perspectives on cardiac amyloidosis.
Current treatment in cardiac amyloidosis.
Current trends in diagnosis and management of cardiac amyloidosis.
Cutaneous lymphatic amyloid deposits in "Hungarian-type" familial transthyretin amyloidosis: a case report.
Cyclodextrin, a novel therapeutic tool for suppressing amyloidogenic transthyretin misfolding in transthyretin-related amyloidosis.
Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: a likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S/V30M transgenic mice?
Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions.
Cysteine 10 is a key residue in amyloidogenesis of human transthyretin Val30Met.
D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?
Dangerous relationships: aortic stenosis and transthyretin cardiac amyloidosis.
Days alive and outside of hospital from diagnosis of transthyretin vs. light chain cardiac amyloidosis.
Delayed diagnosis of transthyretin amyloidosis with a novel mutation (c.210T>A) in the transthyretin gene.
Demyelinating Neuropathy in a Patient Treated With Revusiran for Transthyretin (Thr60Ala) Amyloidosis.
Derivatization strategies for CE-LIF analysis of biomarkers: Toward a clinical diagnostic of familial transthyretin amyloidosis.
Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
Design of mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and new structural templates.
Detection and characterization of aggregates, prefibrillar amyloidogenic oligomers, and protofibrils using fluorescence spectroscopy.
Detection of genetic variants of transthyretin by liquid chromatography-dual electrospray ionization fourier-transform ion-cyclotron-resonance mass spectrometry.
Detection of high-molecular-weight amyloid serum protein complexes using biological on-line tracer sedimentation.
Detection of serum amyloid A-derived proteins in formalin-fixed paraffin-embedded tissues: reliability of the method and expansion of its spectrum.
Development and validation of a liquid chromatography-tandem mass spectrometry method for the assay of tafamidis in rat plasma: Application to a pharmacokinetic study in rats.
Development and validation of a TTR-specific copy number screening tool, and application to potentially relevant patient cohorts.
Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients.
Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS?+?7.
Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening.
Diagnosis and therapeutic approaches to transthyretin amyloidosis.
Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis.
Diagnosis and treatment of heart failure in hereditary transthyretin amyloidosis.
Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope.
Diagnosis of amyloid neuropathy.
Diagnosis of cardiac amyloidosis by magnetic resonance imaging due to a new mutation in the transthyretin gene.
Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers.
Diagnosis of cardiac transthyretin amyloidosis based on multimodality imaging.
Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis.
Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy.
Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis.
Diagnostic performance of transthyretin measurement in fat tissue of patients with ATTR amyloidosis.
Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis.
Dietary curcumin counteracts extracellular transthyretin deposition: insights on the mechanism of amyloid inhibition.
Different NT-proBNP circulating levels for different types of cardiac amyloidosis.
Differential expression of Cathepsin E in transthyretin amyloidosis: from neuropathology to the immune system.
Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study.
Diffuse Alveolar Septal Amyloidosis with Wild-Type Transthyretin with Spontaneous Lung Hematoma.
Diflunisal for ATTR Cardiac Amyloidosis.
Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center's experience.
Direct Tissue Evaluation via Immunofluorescence: in the Diagnosis of Hereditary Transthyretin Cardiac Amyloidosis.
Discordant Findings on 18F-NaF and 99mTc-HDP Bone Scans in a Patient With ATTR Cardiac Amyloidosis.
Discordant phenotype in monozygotic female twins with Lys35Thr TTR familial amyloidotic polyneuropathy.
Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective.
Disruption of blood-nerve barriers in hereditary transthyretin (ATTR) amyloidosis.
Dissecting the structure, thermodynamic stability, and aggregation properties of the A25T transthyretin (A25T-TTR) variant involved in leptomeningeal amyloidosis: identifying protein partners that co-aggregate during A25T-TTR fibrillogenesis in cerebrospinal fluid.
Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities.
Domino liver transplantation: full-length transthyretin in donor and recipient patients with ATTR Val30Met amyloidosis.
Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study.
Drug discovery targeted at transthyretin cardiac amyloidosis: rational design, synthesis, and biological activity of new transthyretin amyloid inhibitors.
Early cardiac involvement in senile systemic amyloidosis: a case report.
Early destructive spondyloarthropathy from combined beta2-microglobulin and transthyretin Met30 amyloidosis in a dialysed patient.
Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations.
Early onset vitreous amyloidosis in familial amyloidotic polyneuropathy with a transthyretin Glu54Gly mutation is associated with elevated vitreous VEGF.
Early skin denervation in hereditary and iatrogenic transthyretin amyloid neuropathy.
Echocardiographic and Biohumoral Characteristics in Patients With AL and TTR Amyloidosis at Diagnosis.
Echocardiographic and pathologic findings of wild-type transthyretin senile systemic amyloidosis developed in early 50s.
Editorial: Transthyretin: a small protein in the big world of amyloidoses.
Effect of age and sex differences on wild-type transthyretin amyloid formation in familial amyloidotic polyneuropathy: a proteomic approach.
Effect of cyclodextrins on transthyretin amyloid formation in transthyretin-related amyloidosis.
Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis.
Effect of nitric oxide in amyloid fibril formation on transthyretin-related amyloidosis.
Effects of Chronic Stress on Prefrontal Cortex Transcriptome in Mice Displaying Different Genetic Backgrounds.
Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report.
Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis.
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study.
Elderly onset vitreous opacities as the initial manifestation in hereditary transthyretin (ATTR Val30Met) carries.
Emerging Advances in the Management of Cardiac Amyloidosis.
Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis.
Emerging Therapies for Transthyretin Cardiac Amyloidosis.
End-stage renal failure due to transthyretin amyloidosis after liver transplantation: outcomes in 19 registry cases.
Endoplasmic reticulum quality control regulates the fate of transthyretin variants in the cell.
Enhanced amyloidogenicity of sulfonated transthyretin in vitro, a hypothetical etiology of senile amyloidosis.
Enhanced transthyretin tetramer stability following expression of an amyloid disease transsuppressor variant in mammalian cells.
Enthalpic Forces Correlate with the Selectivity of Transthyretin-Stabilizing Ligands in Human Plasma.
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
Erratum to: Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
Estimating cancer risk from 99mTc pyrophosphate imaging for transthyretin cardiac amyloidosis.
Estimating the prevalence of allelic variants in the transthyretin gene by analysing large-scale sequencing data.
Etiology of Amyloidosis Determines Myocardial 99mTc-DPD Uptake in Amyloidotic Cardiomyopathy.
Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma.
Evidence of the presence of amyloid substance in the blood of familial amyloidotic polyneuropathy patients with ATTR Val30Met mutation.
Evidence that glial cells attenuate G47R transthyretin accumulation in the central nervous system.
Evolution of amyloid fibrils in hereditary transthyretin amyloidosis: an ultrastructural study.
Evolutionary changes to transthyretin: structure-function relationships.
Evolving landscape in the management of transthyretin amyloidosis.
Examining the sensitivity of 18F-NaF PET for the imaging of cardiac amyloidosis.
Exome analysis of connective tissue dysplasia: Death and rebirth of clinical genetics?
Experimental Inhibition of Fibrillogenesis and Neurotoxicity by amyloid-beta (A?) and Other Disease-Related Peptides/Proteins by Plant Extracts and Herbal Compounds.
Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.
EXPRESS: Riociguat for the treatment of transthyretin cardiac amyloidosis - Data from a named patient use program in Austria.
Expression of a synthetic gene encoding human transthyretin in Escherichia coli.
Expression, purification, and in vitro cysteine-10 modification of native sequence recombinant human transthyretin.
Extensive intracranial microbleeds in transthyretin amyloidosis.
Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds.
Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study.
Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
Familial amyloid cardiomyopathy masquerading as chronic Guillain-Barre syndrome: things are not always what they seem.
Familial amyloid polyneuropathy type I (Portuguese): distribution and characterization of renal amyloid deposits.
Familial amyloid polyneuropathy.
Familial amyloidosis in a large Spanish kindred resulting from a D38V mutation in the transthyretin gene.
Familial amyloidosis with polyneuropathy associated with TTR Ser50Arg mutation.
Familial amyloidotic polyneuropathy and transthyretin.
Familial amyloidotic polyneuropathy type 1 in Brazil is associated with the transthyretin Val30Met variant.
Familial amyloidotic polyneuropathy: a new transthyretin position 30 mutation (alanine for valine) in a family of German descent.
Familial amyloidotic polyneuropathy: protein aggregation in the peripheral nervous system.
Familial Approach in Hereditary Transthyretin Cardiac Amyloidosis.
Familial approach in hereditary transthyretin cardiac amyloidosis.
Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy.
Familial leptomeningeal amyloidosis with a transthyretin variant Asp18Gly representing repeated subarachnoid haemorrhages with superficial siderosis.
Familial meningocerebrovascular amyloidosis, Hungarian type, with mutant transthyretin (TTR Asp18Gly)
Familial Transthyretin Amyloidosis with Variant Asp38Ala Presenting with Orthostatic Hypotension and Chronic Diarrhea.
Familial vitreous amyloidosis resulting from transthyretin variant Gly83Arg.
Family studies of the genetic abnormality in transthyretin (prealbumin) in Portuguese patients with familial amyloidotic polyneuropathy.
Fatal cerebral haemorrhage after liver transplantation in a patient with transthyretin variant (gly53glu) amyloidosis.
FDA approves patisiran to treat hereditary transthyretin amyloidosis.
Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience.
Fibril in senile systemic amyloidosis is derived from normal transthyretin.
Fibroblasts endocytose and degrade transthyretin aggregates in transthyretin-related amyloidosis.
First report of a rare mutation in a Polish patient with painful late-onset transthyretin amyloidosis.
First-in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers.
Flavonoid interactions with human transthyretin: Combined structural and thermodynamic analysis.
Fluorotryptophan incorporation modulates the structure and stability of transthyretin in a site-specific manner.
Founder effect of the Glu89Gln TTR mutation in the Bulgarian population.
Frequency and genetic background of the position 122 (Val----Ile) variant transthyretin gene in the black population.
FRET studies of various conformational states adopted by transthyretin.
From renal amyloid deposits to the identification of the culprit genes.
Functional Amyloid Signaling via the Inflammasome, Necrosome, and Signalosome: New Therapeutic Targets in Heart Failure.
Functional variation of the transthyretin gene among human populations and its correlation with amyloidosis phenotypes.
Gastric emptying in hereditary transthyretin amyloidosis: the impact of autonomic neuropathy.
Gastric peroral endoscopic myotomy for transthyretin amyloidosis gastroparesis.
Gastrointestinal amyloidosis associated with transthyretin Phe64Ser mutation.
Gastrointestinal Tract Amyloidosis Presenting With Pneumatosis Intestinalis.
Gene expression profile in hereditary transthyretin amyloidosis: differences in targeted and source organs.
Gene-targeting pharmaceuticals for single-gene disorders.
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis.
Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan.
Genetic anticipation in Portuguese kindreds with familial amyloidotic polyneuropathy is unlikely to be caused by triplet repeat expansions.
Genetic microheterogeneity of human transthyretin detected by IEF.
Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies.
Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy.
Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis.
Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt).
Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis.
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
Genotype, echocardiography, and survival in familial transthyretin amyloidosis.
Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study.
Green tea halts progression of cardiac transthyretin amyloidosis: an observational report.
Guideline of transthyretin-related hereditary amyloidosis for clinicians.
Heart complications in familial transthyretin amyloidosis: impact of age and gender.
Heart failure and cardiac involvement as isolated manifestation of familial form of transthyretin amyloidosis resulting from Val30Met mutation with no clinical signs of polyneuropathy.
Heart failure caused by a novel amyloidogenic mutation of the transthyretin gene: ATTR Ala45Ser.
Heart Failure Complicated by Alveolar Hemorrhage due to Vascular Collapse and Amyloid Deposits in Wild-Type Transthyretin Amyloidosis.
Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study.
Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis.
Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis.
Heart transplantation in a 68-year-old patient with senile systemic amyloidosis.
Heart transplantation in cardiac amyloidosis.
Hepatocyte-like cells reveal novel role of SERPINA1 in transthyretin amyloidosis.
Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1.
Hereditary ATTR Amyloidosis with Cardiomyopathy Caused by the Novel Variant Transthyretin Y114S (p.Y134S).
Hereditary ATTR amyloidosis: a single-institution experience with 266 patients.
Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Hereditary cardiac amyloidosis associated with the transthyretin Ile122 mutation in a white man.
Hereditary transthyretin amyloidosis associated with a transthyretin variant Thr59Arg.
Hereditary transthyretin amyloidosis from a Scandinavian perspective.
Hereditary Transthyretin Amyloidosis in Eight Chinese Families.
Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.
Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.
Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies.
High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly.
Highly selective leptomeningeal amyloidosis with transthyretin variant Ala25Thr.
Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier?
Homozygosity for the V122I mutation in transthyretin is associated with earlier onset of cardiac amyloidosis in the African American population in the seventh decade of life.
Homozygous transthyretin mutation in an African American Male.
How your ears can tell what is hidden in your heart: wild-type transthyretin amyloidosis as potential cause of sensorineural hearing loss inelderly-AmyloDEAFNESS pilot study.
Human TTRV30M localization within podocytes in a transgenic mouse model of transthyretin related amyloidosis: does the environment play a role?
Human-murine transthyretin heterotetramers are kinetically stable and non-amyloidogenic. A lesson in the generation of transgenic models of diseases involving oligomeric proteins.
Hydration and packing are crucial to amyloidogenesis as revealed by pressure studies on transthyretin variants that either protect or worsen amyloid disease.
Hydrogen-bond network and pH sensitivity in transthyretin: Neutron crystal structure of human transthyretin.
Hydroxymethylene diphosphonate for imaging transthyretin cardiac amyloidosis.
Iatrogenic amyloid polyneuropathy after domino liver transplantation.
Identification of a novel transthyretin Thr59Lys/Arg104His. A case of compound heterozygosity in a Chinese patient diagnosed with familial transthyretin amyloidosis.
Identification of a novel TTR Gly67Glu mutant and the first case series of familial transthyretin amyloidosis in Hong Kong Chinese.
Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
Identification of S-sulfonation and S-thiolation of a novel transthyretin Phe33Cys variant from a patient diagnosed with familial transthyretin amyloidosis.
Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging.
Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure?
Imaging in systemic amyloidosis.
Imaging of cardiac amyloidosis by (99m)Tc-PYP scintigraphy.
Immunoaffinity chromatographic and immunoprecipitation methods combined with mass spectrometry for characterization of circulating transthyretin.
Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients.
Immunostaining images of vitreous transthyretin amyloid.
Impact of age and amyloidosis on thiol conjugation of transthyretin in hereditary transthyretin amyloidosis.
Impact of aging on the progression of neuropathy after liver transplantation in transthyretin Val30Met amyloidosis.
Impact of clinical and echocardiographic characteristics on occurrence of cardiac events in cardiac amyloidosis as proven by endomyocardial biopsy.
Impact of Deuteration on the Assembly Kinetics of Transthyretin Monitored by Native Mass Spectrometry and Implications for Amyloidoses.
Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis.
Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).
Impact of liver transplantation on cardiac autonomic denervation in familial amyloid polyneuropathy.
Impact of liver transplantation on familial amyloidotic polyneuropathy (FAP) patients' symptoms and complications.
Impact of liver transplantation on the natural history of oculopathy in Portuguese patients with transthyretin (V30M) amyloidosis.
Impairment of autophagy by TTR V30M aggregates: in vivo reversal by TUDCA and curcumin.
Importance of Genetic Testing in the Diagnosis of Transthyretin Cardiac Amyloidosis.
Improved electrochemical detection of a transthyretin synthetic peptide in the nanomolar range with a two-electrode system integrated in a glass/PDMS microchip.
Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era.
Improving strategies for the diagnosis of cardiac amyloidosis.
In silico analysis of TTR gene (coding and non-coding regions, and interactive network) and its implications in transthyretin-related amyloidosis.
In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides.
Inclusion body myositis, muscle blood vessel and cardiac amyloidosis, and transthyretin Val122Ile allele.
Inconsistency between hepatic expression and serum concentration of transthyretin in mice humanized at the transthyretin locus.
Increased Risk of Multiple Outpatient Surgeries in African-American Carriers of Transthyretin Val122Ile Mutation Is Modulated by Non-Coding Variants.
Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies.
Indications and diagnostic yield of endomyocardial biopsies for unexplained cardiomyopathy, a single center experience.
Indications for liver transplantation in patients with amyloidosis: a single-center experience with 11 cases.
Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosis.
Ineffectiveness of dialysis in transthyretin (TTR) clearance in familial amyloid polyneuropathy type I, in spite of lower stability of the TTR Met30 variant.
Inflammatory and Molecular Pathways in Heart Failure-Ischemia, HFpEF and Transthyretin Cardiac Amyloidosis.
Inflammatory profiling of patients with familial amyloid polyneuropathy.
Inhibiting transthyretin amyloid fibril formation via protein stabilization.
Inhibition of human transthyretin aggregation by non-steroidal anti-inflammatory compounds: a structural and thermodynamic analysis.
Inhibition of the Amyloidogenesis of Transthyretin by Natural Products and Synthetic Compounds.
Inhibition of transthyretin-met30 expression using Inosine(15.1)-Hammerhead ribozymes in cell culture.
Inhibitory activities of propolis and its promising component, caffeic acid phenethyl ester, against amyloidogenesis of human transthyretin.
Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis.
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
Inotersen: First Global Approval.
Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis.
Inotropic myocardial reserve deficiency is the predominant feature of exercise haemodynamics in cardiac amyloidosis.
Integrated diagnostic approach to wild-type transthyretin cardiac amyloidosis with the use of high-sensitivity cardiac troponin T measurement and 99mTc-pyrophosphate scintigraphy.
Interactions amongst plasma retinol-binding protein, transthyretin and their ligands: implications in vitamin A homeostasis and transthyretin amyloidosis.
Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis.
Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis.
Intracranial and systemic manifestations of familial leptomeningeal amyloidosis, as seen on CT and MRI.
Intramyocardial inflammation predicts adverse outcome in patients with cardiac AL amyloidosis.
Intrinsic versus mutation dependent instability/flexibility: a comparative analysis of the structure and dynamics of wild-type transthyretin and its pathogenic variants.
Investigation into thiol conjugation of transthyretin in hereditary transthyretin amyloidosis.
Investigation of AGE, their receptor and NF-kappaB activation and apoptosis in patients with ATTR and Gelsolin amyloidosis.
Iodination of salicylic acid improves its binding to transthyretin.
Is Transthyretin a Regulator of Ubc9 SUMOylation?
Isolated atrial amyloidosis and the importance of molecular classification.
Isolated heart transplantation for familial transthyretin (TTR) V122I cardiac amyloidosis.
Isolated vitreoretinal amyloidosis in the absence of transthyretin mutations.
Kind and distribution of cutaneous sensation loss in hereditary transthyretin amyloidosis with polyneuropathy.
Kinetic analysis of the multistep aggregation pathway of human transthyretin.
Kinetic assay for high-throughput screening of in vitro transthyretin amyloid fibrillogenesis inhibitors.
Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis.
L55P transthyretin accelerates subunit exchange and leads to rapid formation of hybrid tetramers.
Laboratory assessment of transthyretin amyloidosis.
Late-onset hereditary ATTR V30M amyloidosis with polyneuropathy: Characterization of Brazilian subjects from the THAOS registry.
Latent Class Analysis to Classify Patients with Transthyretin Amyloidosis by Signs and Symptoms.
Left Atrial Morphology, Size and Function in Patients With Transthyretin Cardiac Amyloidosis and Primary Hypertrophic Cardiomyopathy?- Comparative Strain Imaging Study.
Left atrial structure and function in cardiac amyloidosis.
Left Ventricular Structure and Function in TTR-Related versus AL Cardiac Amyloidosis.
Length-dependent truncal A?-fiber dysfunction in hereditary transthyretin amyloidosis: An intra-epidermal electrical stimulation study.
Leukocyte Chemotactic Factor 2 (LECT2)-Associated Renal Amyloidosis: A Case Series.
Light-chain cardiac amyloidosis.
Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families.
Liver transplantation and transthyretin amyloidosis.
Liver transplantation for familial amyloidotic polyneuropathy in Australia.
Liver transplantation for hereditary transthyretin amyloidosis.
Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?
Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients.
Liver transplantation in transthyretin amyloidoses. When the neurological benefit outweighs the risk.
Liver transplantation in transthyretin amyloidosis: Characteristics and management related to kidney disease.
Liver transplantation in transthyretin amyloidosis: Issues and challenges.
Long-term follow-up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type).
Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy.
Long-term outcome of patients with hereditary transthyretin V30M amyloidosis with polyneuropathy after liver transplantation.
Loss of gastric interstitial cells of Cajal in patients with hereditary transthyretin amyloidosis.
Low plasma apolipoprotein AII levels in human and mouse amyloidosis with mutant transthyretin (Met-30) gene.
Lumbosacral stenosis in Labrador retriever military working dogs - an exomic exploratory study.
Lysozyme amyloidosis: report of 4 cases and a review of the literature.
Macroglossia - not always AL amyloidosis.
Magnetic Resonance in Transthyretin Cardiac Amyloidosis.
Management of gastrointestinal complications in hereditary transthyretin amyloidosis: a single-center experience over 40 years.
Marked Systemic Amyloid Angiopathy in Patients With Val 107 Transthyretin Mutation.
Mass Spectrometric-Based Proteomic Analysis of Amyloid Neuropathy Type in Nerve Tissue.
Massive leptomeningeal amyloidosis associated with a Val30Met transthyretin gene.
Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.
Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging.
Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis.
Mechanisms of heart failure in transthyretin vs. light chain amyloidosis.
Mechanisms of transthyretin aggregation and toxicity.
Mechanisms of transthyretin amyloidogenesis. Antigenic mapping of transthyretin purified from plasma and amyloid fibrils and within in situ tissue localizations.
Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs.
Medullary amyloidosis associated with apolipoprotein A-IV deposition.
Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD 18G)
Metabolic turn over of amyloid fibrils and post-treatment regression of amyloid deposits in systemic amyloidosis with polyneuropathy.
Metabolism of amyloid proteins.
Methods to evaluate the inhibition of TTR fibrillogenesis induced by small ligands.
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.
Misfolded transthyretin causes behavioral changes in a Drosophila model for transthyretin-associated amyloidosis.
Mispacking of the Phe87 side chain reduces the kinetic stability of human transthyretin.
Mitochondrial haplogroup is associated with the phenotype of familial amyloidosis with polyneuropathy in Swedish and French patients.
Modeling familial amyloidotic polyneuropathy (Transthyretin V30M) in Drosophila melanogaster.
Modifications of the 7-Hydroxyl Group of the Transthyretin Ligand Luteolin Provide Mechanistic Insights into Its Binding Properties and High Plasma Specificity.
Modulating inhibitors of transthyretin fibrillogenesis via sulfation: Polychlorinated biphenyl sulfates as models.
Molecular Imaging of Cardiac Amyloidosis.
Molecular Tweezers Targeting Transthyretin Amyloidosis.
Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
Monoclonal Gammopathy of Uncertain Significance and Transthyretin Cardiac Amyloidosis.
Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).
Most recent common ancestor of TTR Val30Met mutation in Italian population and its potential role in genotype-phenotype correlation.
Mucocutaneous manifestations in systemic amyloidosis A retrospective analytical study in a tertiary care center.
Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis.
Multimodality Imaging of Cardiac Transthyretin Amyloidosis 16 years after a Domino Liver Transplantation.
Multisystemic Disease Modeling of Liver-Derived Protein Folding Disorders Using Induced Pluripotent Stem Cells (iPSCs).
Mutation p.G83R in the transthyretin gene is associated with hereditary vitreous amyloidosis in Han Chinese families.
Myocardial Amyloidosis: The Exemplar Interstitial Disease.
Myocardial Contraction Fraction by M-Mode Echocardiography Is Superior to Ejection Fraction in Predicting Mortality in Transthyretin Amyloidosis.
Myocardial Edema and Prognosis in Amyloidosis.
Myocardial hypertrophy and function are related to age at onset in familial amyloidotic polyneuropathy.
Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis.
Myocardial Oxygen Consumption and Efficiency in Patients With Cardiac Amyloidosis.
National patterns in imaging utilization for diagnosis of cardiac amyloidosis: A focus on Tc99m-pyrophosphate scintigraphy.
Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.
Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants.
Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
Native T1 mapping in transthyretin amyloidosis.
Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System.
Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.
Neuroarthropathy secondary to transthyretin amyloidosis (ATTR V30M).
Neuronal production of transthyretin in human and murine Alzheimer's disease: is it protective?
Neuroradiologic and clinicopathologic features of oculoleptomeningeal type amyloidosis.
Neutrophil proteases associated with amyloid fibrils.
New insights into the clinical evaluation of hereditary transthyretin amyloidosis patients: a single center's experience.
New Medications in the Treatment of Hereditary Transthyretin Amyloidosis.
New pathological insights into cardiac amyloidosis: implications for non-invasive diagnosis.
New sequence variants in patients affected by amyloidosis show transthyretin instability by isoelectric focusing.
New simple and quick method to analyze serum variant transthyretins: direct MALDI method for the screening of hereditary transthyretin amyloidosis.
New structural information and update on liver transplantation in transthyretin-associated amyloidosis. Report from the 4th International Symposium on Familial Amyloidotic Polyneuropathy and Other Transthyretin Related Disorders & the 3rd International Workshop on Liver Transplantation in Familial Amyloid Polyneuropathy, Umeå Sweden, June 1999.
Newer Therapies for Amyloid Cardiomyopathy.
No association between apolipoprotein E epsilon4 allele and the age of onset in type I familial amyloid polyneuropathy.
Nodular cutaneous amyloidosis and carpal tunnel syndrome due to the amyloidogenic transthyretin His 114 variant.
Nodular senile pulmonary amyloidosis: a unique case confirmed by immunohistochemistry, mass spectrometry, and genetic study.
Non-cardiac uptake of technetium-99m pyrophosphate in transthyretin cardiac amyloidosis.
Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives.
Non-invasive cardiac imaging methods in transthyretin amyloidosis.
Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance.
Non-invasive predictors of survival in cardiac amyloidosis.
Non-senile wild-type transthyretin systemic amyloidosis presenting as bilateral carpal tunnel syndrome.
Non-Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis.
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.
Noncerebral Amyloidoses: Aspects on Seeding, Cross-Seeding, and Transmission.
Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis.
Noninvasive detection of cardiac involvement in patients with hereditary transthyretin associated amyloidosis using cardiac magnetic resonance imaging: a prospective study.
Noninvasive diagnosis of hereditary transthyretin-related cardiac amyloidosis: A case report.
Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy.
Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities.
Noninvasive Risk Stratification of Patients With Transthyretin Amyloidosis.
Normal scores of deep breathing tests: beware of dysrhythmia in transthyretin amyloidosis.
Normal transthyretin and synthetic transthyretin fragments form amyloid-like fibrils in vitro.
Novel Antibody for the Treatment of Transthyretin Amyloidosis.
Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin.
Novel drugs targeting transthyretin amyloidosis.
Novel methods for detecting amyloidogenic proteins in transthyretin related amyloidosis.
Novel pharmacotherapies for cardiac amyloidosis.
Novel screening for transthyretin amyloidosis by using fat ultrasonography.
Novel transthyretin missense mutation (Thr34) in an Italian family with hereditary amyloidosis.
Novel variant transthyretin gene (Ser50 to Ile) in familial cardiac amyloidosis.
Novel Zn2+-binding sites in human transthyretin: implications for amyloidogenesis and retinol-binding protein recognition.
Nuclear tracers for transthyretin cardiac amyloidosis: time to bone up?
Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement.
Occurrence factors and clinical picture of iatrogenic transthyretin amyloidosis after domino liver transplantation.
Ocular amyloidosis, with special reference to the hereditary forms with vitreous involvement.
Ocular manifestations in hereditary transthyretin Gly67Glu amyloidosis.
Ocular Manifestations of Familial Transthyretin Amyloidosis.
Oculoleptomeningeal amyloidosis associated with a new transthyretin variant Ser64.
Oculoleptomeningeal Amyloidosis associated with transthyretin Leu12Pro in an African patient.
Oculoleptomeningeal amyloidosis in 3 individuals with the transthyretin variant Tyr69His.
Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His.
Oculoleptomeningeal amyloidosis in a patient with a TTR Val30Gly mutation in the transthyretin gene.
Oculoleptomeningeal Amyloidosis Secondary to the Rare Transthyretin c.381T>G (p.Ile127Met) Mutation.
Old men and thickened hearts.
Oligomeric TTR V30M aggregates compromise cell viability, erythropoietin gene expression and promoter activity in the human hepatoma cell line Hep3B.
Oligonucleotide Drugs for Transthyretin Amyloidosis.
On-a-chip tryptic digestion of transthyretin: a step toward an integrated microfluidic system for the follow-up of familial transthyretin amyloidosis.
On-line immunoaffinity solid-phase extraction capillary electrophoresis mass spectrometry using Fab´antibody fragments for the analysis of serum transthyretin.
One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition.
Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis.
Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan.
Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management.
Orthotopic liver transplantation for familial amyloidotic polyneuropathy: a pathological study.
Osteo-articular manifestations of amyloidosis.
Ostertag revisited: the inherited systemic amyloidoses without neuropathy.
Outcome in patients treated with isolated liver transplantation for familial transthyretin amyloidosis to prevent cardiomyopathy.
Outcome of exercise electrocardiography in familial amyloidotic polyneuropathy patients, Portuguese type, under evaluation for liver transplantation.
Outcome of gastric emptying and gastrointestinal symptoms after liver transplantation for hereditary transthyretin amyloidosis.
Outcome of liver transplantation for transthyretin amyloidosis: follow-up of Japanese familial amyloidotic polyneuropathy patients.
Outcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis.
Outcomes of Patients With Familial Transthyretin Amyloidosis After Liver Transplantation.
Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy.
Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses.
Pathogenesis of transthyretin amyloidosis.
Pathological changes long after liver transplantation in a familial amyloidotic polyneuropathy patient.
Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis.
Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
Pattern of myocardial 99mTc-HMDP uptake and impact on myocardial function in patients with transthyretin cardiac amyloidosis.
Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures.
Peripheral nerve ultrasonography in patients with transthyretin amyloidosis.
Persistent Troponin Elevation in a Patient with Cardiac Amyloidosis.
Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy).
Pharmacokinetics of Tafamidis, a Transthyretin Amyloidosis Drug, in Rats.
Pharmacological Stimulation of Phagocytosis Enhances Amyloid Plaque Clearance; Evidence from a Transgenic Mouse Model of ATTR Neuropathy.
Phenotypes of Late-Onset Transthyretin Amyloid Neuropathy: A Diagnostic Challenge.
Phenotypic characterization of late onset cardiac amyloidosis caused by the transthyretin mutation TTRA45S, p.(Ala65Ser).
Phenotypic expression of familial amyloid polyneuropathy in Brazil.
Phenotypic expressions of hereditary Transthyretin Ala97Ser related Amyloidosis (ATTR) in Taiwanese.
Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure.
Physiological IgM class catalytic antibodies selective for transthyretin amyloid.
Pieter Cullis' quest for a lipid-based, fusogenic delivery system for nucleic acid therapeutics: success with siRNA so what about mRNA?
Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis.
Pompe Disease Could Mimic Exam Findings of Amyloidosis: Two Rare Diagnoses Bona Fide.
Population diversity of the genetically determined TTR expression in human tissues and its implications in TTR amyloidosis.
Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR).
Potential treatment of transthyretin-type amyloidoses by sulfite.
Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis.
Prediction of long-term survival after liver transplantation for familial transthyretin amyloidosis.
Predictive model of response to tafamidis in hereditary ATTR polyneuropathy.
Predictors of survival stratification in patients with wild-type cardiac amyloidosis.
Prenatal diagnosis of hereditary amyloidosis in a Portuguese family living in France.
Pressure-Volume Relationships in Patients With Transthyretin (ATTR) Cardiac Amyloidosis Secondary to V122I Mutations and Wild-Type Transthyretin: Transthyretin Cardiac Amyloid Study (TRACS).
Prevalence and origin of amyloid in kidney biopsies.
Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders.
Prevalence of Monoclonal Gammopathy in Wild-Type Transthyretin Amyloidosis.
Prevalence of Positive 99 mTc-DPD Scintigraphy as an Indicator of the Prevalence of Wild-type Transthyretin Amyloidosis in the Elderly.
Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14?333 African-Americans.
Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population.
Prevention of transthyretin amyloid disease by changing protein misfolding energetics.
Probing conformational changes of monomeric transthyretin with second derivative fluorescence.
Probing solvent accessibility of transthyretin amyloid by solution NMR spectroscopy.
Production and functional analysis of normal and variant recombinant human transthyretin proteins.
Prognostic impact of light-chain and transthyretin-related categories in cardiac amyloidosis: a systematic review and meta-analysis.
Prognostic implication of relative regional strain ratio in cardiac amyloidosis.
Prognostic Significance of Occult Transthyretin Cardiac Amyloidosis in Patients With Severe Aortic Stenosis Undergoing Surgical Aortic Valve Replacement: An Unrecognized Disease Modifier.
Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid.
Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis.
Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation.
Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type.
Progression of cardiomyopathy and neuropathy after liver transplantation in a patient with familial amyloidotic polyneuropathy caused by tyrosine-77 transthyretin variant.
Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation-a prospective single-center cohort study.
Progression of transthyretin amyloid neuropathy after liver transplantation.
Proportion between wild-type and mutant protein in truncated compared to full-length ATTR: an analysis on transplanted transthyretin T60A amyloidosis patients.
Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS).
Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis.
Proteome analysis of cerebrospinal fluid in Guillain-Barré syndrome (GBS).
Proteomic analysis of inclusion body myositis.
Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations.
Purification of transthyretin and transthyretin fragments from amyloid-rich human tissues.
Q-Rich Yeast Prion [
Quadriceps tendon rupture in wild-type transthyretin amyloidosis (ATTRwt).
Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis.
Quantification of transthyretin kinetic stability in human plasma using subunit exchange.
Quantitation of 99mTc-DPD uptake in patients with transthyretin-related cardiac amyloidosis.
Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy.
Quaternary structure, aggregation and cytotoxicity of transthyretin.
Rapid detection of wild-type and mutated transthyretins.
Rapid method to characterize mutations in transthyretin in cerebrospinal fluid from familial amyloidotic polyneuropathy patients by use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
Rapidly Progressive Transthyretin-Mediated Amyloidosis in a Domino Liver Transplant Recipient of a Ser23Asn Donor.
Rate of progression of transthyretin amyloidosis.
Rational design of potent human transthyretin amyloid disease inhibitors.
Recent Advances in Oligonucleotide-Based Therapy for Transthyretin Amyloidosis: Clinical Impact and Future Prospects.
Recent advances in the diagnosis and management of cardiac amyloidosis.
Recent advances in the noninvasive strategies of cardiac amyloidosis.
Recent advances in transthyretin amyloidosis therapy.
Recent progress in the understanding and treatment of transthyretin amyloidosis.
Recipient Aging Accelerates Acquired Transthyretin Amyloidosis After Domino Liver Transplantation.
Recognizing Transthyretin Cardiac Amyloidosis in Patients With Aortic Stenosis: Impact on Prognosis.
Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis.
Recurrent subarachnoid hemorrhage associated with a new transthyretin variant (Gly53Glu).
Reduced intraepidermal nerve fibre density in patients with hereditary transthyretin amyloidosis.
Reduced left atrial myocardial deformation irrespective of cavity size: a potential cause for atrial arrhythmia in hereditary transthyretin amyloidosis.
Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy.
Reduced trans-mitral A-wave velocity predicts the presence of wild-type transthyretin amyloidosis in elderly patients with left ventricular hypertrophy.
Reduction of free radical activity in amyloid deposits following liver transplantation for familial amyloidotic polyneuropathy.
Regional Variation in Technetium Pyrophosphate Uptake in Transthyretin Cardiac Amyloidosis and Impact on Mortality.
Relation of clinical, echocardiographic and electrocardiographic features of cardiac amyloidosis to the presence of the transthyretin V122I allele in older African-American men.
Relationship between amyloid deposition and intracellular structural changes in familial amyloidotic polyneuropathy.
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue.
Renal Infarction and Its Consequences for Renal Function in Patients With Cardiac Amyloidosis.
Reply: Liver transplantation in transthyretin amyloidosis: Issues and challenges.
Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity.
Response: Atrial impairment in transthyretin cardiac amyloidosis: an early marker of cardiac involvement and a prognostic factor.
Restriction fragment length polymorphism analysis of mutated transthyretin in vitreous amyloidosis.
Restrictive cardiomyopathy in inherited ATTR amyloidosis (TTR-Ser23Asn) in a patient of German-Italian extraction.
Results of liver transplantation for familial amyloid polyneuropathy type I in Brazil.
Retinol binding protein 4 (RBP4) concentration identifies V122I transthyretin cardiac amyloidosis.
Review: TTR amyloidosis-structural features leading to protein aggregation and their implications on therapeutic strategies.
Revised transthyretin Ile 122 allele frequency in African-Americans.
Revisiting transthyretin related cardiac amyloidosis: Case report and review of literature.
Right ventricular involvement in transthyretin amyloidosis.
Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation.
Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis.
Role of Right Ventricular Strain Measured by Two-Dimensional Echocardiography in the Diagnosis of Cardiac Amyloidosis.
Role of serum amyloid P component for systemic amyloidosis in transgenic mice carrying human mutant transthyretin gene.
Role of the glutamic acid 54 residue in transthyretin stability and thyroxine binding.
S-sulfonation of transthyretin is an important trigger step in the formation of transthyretin-related amyloid fibril.
Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis.
Safety and efficacy of RNAi therapy for transthyretin amyloidosis.
Scavenger treatment of free radical injury in familial amyloidotic polyneuropathy: a study on Swedish transplanted and non-transplanted patients.
Schwann cells contribute to neurodegeneration in transthyretin amyloidosis.
Scientific Advances in and Clinical Approaches to Small-Fiber Polyneuropathy: A Review.
Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins.
Selection of hereditary transthyretin amyloid patients for liver transplantation: the Swedish experience.
Selective silencing of a mutant transthyretin allele by small interfering RNAs.
Self-reported gastrointestinal symptoms are more common in liver transplanted transthyretin amyloidosis patients than in healthy controls and in patients transplanted for end-stage liver disease.
Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
Senile cardiac amyloidosis associated with homozygosity for a transthyretin variant (ILE-122).
Senile cardiac amyloidosis: an underappreciated cause of heart failure.
Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study.
Senile Systemic Amyloidosis: An Underdiagnosed Disease.
Senile systemic amyloidosis: clinical features at presentation and outcome.
Senile transthyretin cardiac amyloidosis in patients with plasma cell dyscrasias: importance of cardiac biopsy for making the correct diagnosis.
Serial scanning with technetium pyrophosphate ((99m)Tc-PYP) in advanced ATTR cardiac amyloidosis.
Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis.
Serum Proteomic Variability Associated with Clinical Phenotype in Familial Transthyretin Amyloidosis (ATTRm).
Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity.
Serum transthyretin monomer in patients with familial amyloid polyneuropathy.
Serum Transthyretin: Predictor of Amyloidosis Outcomes?
Seven factors predict a delayed diagnosis of cardiac amyloidosis.
Severe heart disease in an unusual case of familial amyloid polyneuropathy type I.
Single-centre experience of liver transplantation for familial amyloidotic polyneuropathy of non-Val30Met variants in Chinese patients.
Small fiber neuropathy: Diagnosis, causes, and treatment.
Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses.
Small-Molecule Screening for Genetic Diseases.
Solar Eruption in Hereditary Transthyretin Amyloidosis.
Specific Disruption of Transthyretin(105-115) Fibrilization Using "Stabilizing" Inhibitors of Transthyretin Amyloidogenesis.
Specific pathogen free conditions prevent transthyretin amyloidosis in mouse models.
Speckle tracking echo to assess transthyretin amyloidosis type: is it useful (or necessary)?
Spectrum of Restrictive and Infiltrative Cardiomyopathies: Part 1 of a 2-Part Series.
Spinal multifocal amyloidosis derived from wild-type transthyretin.
Spinal Stenosis in Familial Transthyretin Amyloidosis.
Sporadic transthyretin amyloidosis with a novel TTR gene mutation misdiagnosed as primary amyloidosis.
Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful?
Standardization of (99m)Technetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis.
State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis.
Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy.
Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing.
Structural evidence for asymmetric ligand binding to transthyretin.
Structural insights into a zinc-dependent pathway leading to Leu55Pro transthyretin amyloid fibrils.
Structural Stabilization of Human Transthyretin by Centella asiatica (L.) Urban Extract: Implications for TTR Amyloidosis.
Structure of Met30 variant of transthyretin and its amyloidogenic implications.
Structure of Monomeric Transthyretin Carrying the Clinically Important T119M Mutation.
Structure-activity relationships of flurbiprofen analogues as stabilizers of the amyloidogenic protein transthyretin.
Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses.
Studies on plasma transthyretin (prealbumin) in familial amyloidotic polyneuropathy, Portuguese type.
Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses.
Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis.
Successful Heart and Liver Transplantation in a Swiss Patient With Glu89Lys Transthyretin Amyloidosis.
Supercentenarians and transthyretin amyloidosis: the next frontier of human life extension.
Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro.
Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides.
Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment.
Survival After Transplantation in Patients With Mutations Other Than Val30Met: Extracts From the FAP World Transplant Registry.
Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
Synthesis and evaluation of transthyretin amyloidosis inhibitors containing carborane pharmacophores.
Synthesis and structural analysis of halogen substituted fibril formation inhibitors of Human Transthyretin (TTR).
Synthesis of an analog of the thyroid hormone-binding protein transthyretin via regioselective chemical ligation.
Systemic amyloidosis in laying Japanese quail.
Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met 30) gene. Pathological and immunohistochemical similarity to human familial amyloidotic polyneuropathy, type I.
Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met30) gene. Pathologic similarity to human familial amyloidotic polyneuropathy, type I.
Systemic amyloidosis.
Systemic angiopathy and axonopathy in hereditary transthyretin amyloidosis with Ala97Gly (p. Ala117Gly) mutation: a post-mortem analysis.
Systemic but asymptomatic transthyretin amyloidosis 8 years after domino liver transplantation.
Systemic transthyretin amyloidosis in a patient with bent spine syndrome.
Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review.
Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
Tafamidis for the treatment of transthyretin amyloidosis.
Tafamidis for transthyretin amyloidosis.
Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
Tafamidis, a Noninvasive Therapy for Delaying Transthyretin Familial Amyloid Polyneuropathy: Systematic Review and Meta-Analysis.
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
Tafamidis.
Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
Tafamidis: a review of its use in familial amyloid polyneuropathy.
Targeted Nuclear Imaging Probes for Cardiac Amyloidosis.
Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides.
Targeted Therapeutics for Transthyretin Cardiac Amyloidosis.
Targeting a rare amyloidotic disease through rationally designed polymer conjugates.
Targeting Different Transthyretin Binding Sites with Unusual Natural Compounds.
Targeting transthyretin amyloidosis in the eye with next-generation stabilizers: AT40 displays potent TTR stabilization in the human vitreous.
Tc-99m pyrophosphate imaging for transthyretin cardiac amyloidosis: Importance of estimation of cancer risk with the modality.
Teaching NeuroImages: Morphology of lumbosacral dorsal root ganglia and plexus in hereditary transthyretin amyloidosis.
Teaching NeuroImages: Neuromyopathy in a patient with hereditary transthyretin Thr60Ala amyloidosis.
Technetium 99m pyrophosphate radioisotope for diagnosis and prognosis of transthyretin cardiac amyloidosis: A call for collaboration.
Technetium pyrophosphate myocardial uptake and peripheral neuropathy in a rare variant of familial transthyretin (TTR) amyloidosis (Ser23Asn): a case report and literature review.
Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: Associations with echocardiographic disease severity and outcomes.
Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin Amyloidosis.
Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry.
Tertiary structures of amyloidogenic and non-amyloidogenic transthyretin variants: new model for amyloid fibril formation.
Tetrabromobisphenol A Is an Efficient Stabilizer of the Transthyretin Tetramer.
THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.
THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease.
The Accumulation of Heparan Sulfate S-Domains in Kidney Transthyretin Deposits Accelerates Fibril Formation and Promotes Cytotoxicity.
The beta-slip: a novel concept in transthyretin amyloidosis.
The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin.
The challenging histological diagnosis of transthyretin (ATTR) amyloidosis.
The crystal structure of transthyretin from chicken.
The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors.
The current status of the Transthyretin Amyloidosis Outcomes Survey (THAOS) in Japan.
The demographic, genetic, and clinical characteristics of Brazilian subjects enrolled in the Transthyretin Amyloidosis Outcomes Survey.
The demographic, genetic, and clinical characteristics of Latin American subjects enrolled in the Transthyretin Amyloidosis Outcomes Survey.
The Effectiveness and Value of Patisiran and Inotersen for Hereditary Transthyretin Amyloidosis.
The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients.
The ever-growing understanding of transthyretin amyloidosis nephropathy.
The Evolving Role of Cardiovascular Magnetic Resonance Imaging in the Evaluation of Systemic Amyloidosis.
The first Caucasian patient with p.Val122Ile mutated-transthyretin cardiac amyloidosis treated with isolated heart transplantation.
The flavonoid luteolin, but not luteolin-7-O-glucoside, prevents a transthyretin mediated toxic response.
The genetic heterogeneity of hereditary transthyretin amyloidosis in a sample of the Brazilian population.
The identification of a transthyretin variant p.D38G in a Chinese family with early-onset leptomeningeal amyloidosis.
The importance of a gatekeeper residue on the aggregation of transthyretin: implications for transthyretin-related amyloidoses.
The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients.
The molecular biology and clinical features of amyloid neuropathy.
The morphology of amyloid fibrils and their impact on tissue damage in hereditary transthyretin amyloidosis: An ultrastructural study.
The myocardial contraction fraction is superior to ejection fraction in predicting survival in patients with AL cardiac amyloidosis.
The pathologic spectrum of oculoleptomeningeal amyloidosis with Val30Gly transthyretin gene mutation in a postmortem case.
The pathological and biochemical identification of possible seed-lesions of transmitted transthyretin amyloidosis after domino liver transplantation.
The polyphenol Oleuropein aglycone hinders the growth of toxic transthyretin amyloid assemblies.
The premortem recognition of systemic senile amyloidosis with cardiac involvement.
The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in Africa.
The Prevalence and Management of Systemic Amyloidosis in Western Countries.
The proteome response to amyloid protein expression in vivo.
The relative amounts of plasma transthyretin forms in familial transthyretin amyloidosis: a quantitative analysis by Fourier transform ion-cyclotron resonance mass spectrometry.
The role of fibrinogen glycation in ATTR: evidence for chaperone activity loss in disease.
The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition.
The systemic amyloidoses.
The transmissible amyloidoses: genetical control of spontaneous generation of infectious amyloid proteins by nucleation of configurational change in host precursors: kuru-CJD-GSS-scrapie-BSE.
The transthyretin amyloidoses: advances in therapy.
The Transthyretin Amyloidoses: From Delineating the Molecular Mechanism of Aggregation Linked to Pathology to a Regulatory-Agency-Approved Drug.
The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology.
The transthyretin cDNA sequence is normal in transthyretin-derived senile systemic amyloidosis.
The Truth Is Unfolding About Transthyretin Cardiac Amyloidosis.
The use of subcutaneous fat tissue for amyloid typing by enzyme-linked immunosorbent assay.
The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis.
The Val142Ile transthyretin cardiac amyloidosis: more than an Afro-American pathogenic variant.
The Val142Ile transthyretin cardiac amyloidosis: not only an Afro-American pathogenic variant? A single-centre Italian experience.
Therapeutic Potential of Polyamidoamine Dendrimer for Amyloidogenic Transthyretin Amyloidosis.
Thyroxine binding to transthyretin Met 119. Comparative studies of different heterozygotic carriers and structural analysis.
Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis.
Time Domain Optical Coherence Tomography in Familial Vitreous Amyloidosis Associated Transthyretin Met30 Mutation.
Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture.
Top-Down Analysis of Small Plasma Proteins Using an LTQ-Orbitrap. Potential for Mass Spectrometry-Based Clinical Assays for Transthyretin and Hemoglobin.
Tracheobronchial Amyloidosis in a Patient with Sjögren's Syndrome.
Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation.
Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule.
Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Transthyretin (TTR) Cardiac Amyloidosis.
Transthyretin Ala36Pro mutation in a Chinese pedigree of familial transthyretin amyloidosis with elevated vitreous and serum vascular endothelial growth factor.
Transthyretin Amyloid Fibril Disrupting Activities of Extracts and Fractions from Juglans mandshurica Maxim. var. cordiformis (Makino) Kitam.
Transthyretin Amyloid Goiter in a Renal Allograft Recipient.
Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox?
Transthyretin amyloidoses of familial amyloidotic polyneuropathy as a paradigm for the genetic control of spontaneous generation of infectious amyloids by patterned configurational change in host precursors in Creutzfeldt-Jacob disease.
Transthyretin amyloidosis (serine 44) with headache, hearing loss, and peripheral neuropathy.
Transthyretin amyloidosis and superficial siderosis of the CNS.
Transthyretin amyloidosis and the kidney.
Transthyretin amyloidosis and two other aging-related amyloidoses in an aged vervet monkey.
Transthyretin amyloidosis associated with a novel variant (Trp41Leu) presenting with vitreous opacities.
Transthyretin amyloidosis in a patient of Iranian-Jewish extraction: a second Israeli-Jewish case.
Transthyretin amyloidosis in a septuagenarian masquerading as hypertrophic cardiomyopathy: the importance of multimodality imaging.
Transthyretin amyloidosis in patients with undifferentiated heart failure.
Transthyretin amyloidosis in Western Europe: a snapshot from the THAOS registry and a call for further perspectives.
Transthyretin Amyloidosis Mimicking Obstructive Hypertrophic Cardiomyopathy: A Great Imitator.
Transthyretin amyloidosis presenting with multifocal demyelinating mononeuropathies.
Transthyretin Amyloidosis Presenting With Upper-Extremity Neuropathy and Paucity of Autonomic Impairment.
Transthyretin Amyloidosis with Gastrointestinal Manifestation: a Case Report.
Transthyretin amyloidosis with pulmonary involvement in a patient with monoclonal gammapathy.
Transthyretin Amyloidosis: A "Zebra" of Many Stripes.
Transthyretin amyloidosis: a little history of hereditary amyloidosis.
Transthyretin amyloidosis: a new mutation associated with dementia.
Transthyretin amyloidosis: a phenocopy of hypertrophic cardiomyopathy.
Transthyretin amyloidosis: a tale of weak interactions.
Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy.
Transthyretin Amyloidosis: Chaperone Concentration Changes and Increased Proteolysis in the Pathway to Disease.
Transthyretin and amyloid in the islets of Langerhans in type-2 diabetes.
Transthyretin Arg-83 mutation in vitreous amyloidosis.
Transthyretin Cardiac Amyloidoses in Older North Americans.
Transthyretin Cardiac Amyloidosis and Aortic Stenosis: Connection and Therapeutic Implications.
Transthyretin cardiac amyloidosis diagnosed by analyzing a prostatic tissue sample: a case report.
Transthyretin Cardiac Amyloidosis in Black Americans.
Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Transthyretin Cardiac Amyloidosis in Older Adults: Optimizing Cardiac Imaging to the Corresponding Diagnostic and Management Goal.
Transthyretin Cardiac Amyloidosis in Older Americans.
Transthyretin Cardiac Amyloidosis.
Transthyretin Cardiac Amyloidosis: A Noninvasive Multimodality Approach to Diagnosis Using Transthoracic Echocardiography, 99m-Tc-Labeled Phosphate Bone Scanning, and Cardiac Magnetic Resonance Imaging.
Transthyretin cardiac amyloidosis: an under-diagnosed cause of heart failure.
Transthyretin Cardiac Amyloidosis: From Rare Monogenic Disease to Common Pathway in Heart Failure?
Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction.
Transthyretin chemical chaperoning by flavonoids: Structure-activity insights towards the design of potent amyloidosis inhibitors.
Transthyretin deposition in familial amyloidotic polyneuropathy.
Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis.
Transthyretin familial amyloid polyneuropathy (TTR-FAP): Parameters for early diagnosis.
Transthyretin forms amyloid fibrils at physiological pH with ultrasonication.
Transthyretin Ile 122 and cardiac amyloidosis in African-Americans. 2 case reports.
Transthyretin ILE20, a new variant associated with late-onset cardiac amyloidosis.
Transthyretin is up-regulated by sex hormones in mice liver.
Transthyretin Leu 68 in a form of cardiac amyloidosis.
Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis.
Transthyretin Pro 36 associated with familial amyloidotic polyneuropathy in an Ashkenazic Jewish kindred.
Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement.
Transthyretin Ser 6 gene frequency in individuals without amyloidosis.
Transthyretin Ser-44 mutation in a case with vitreous amyloidosis.
Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution.
Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy.
Transthyretin Stabilizer Is Associated With Expanding Apical Sparing Area and Improving Global Cardiac Function in a Patient With Wild-Type Cardiac Amyloidosis.
Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro.
Transthyretin Tyr69-to-Ile mutation (double-nucleotide substitution in codon 69) in a Japanese familial amyloidosis patient with cardiomyopathy and carpal tunnel syndrome.
Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans.
Transthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy.
Transthyretin VAL107, a new variant associated with familial cardiac and neuropathic amyloidosis.
Transthyretin Val122Ile amyloidosis associated with isolated gastrointestinal disease and bowel rupture in a Caucasian woman.
Transthyretin Val122Ile, accumulated Abeta, and inclusion-body myositis aspects in cultured muscle.
Transthyretin Val30Met mutation in an African American with cardiac amyloidosis.
Transthyretin valine-94-alanine, a novel variant associated with late-onset systemic amyloidosis with cardiac involvement.
Transthyretin-derived amyloidosis: Probably a common cause of lumbar spinal stenosis.
Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations.
Transthyretin-related amyloid in a saphenous vein. Histological diagnosis in a patient undergoing coronary artery bypass surgery.
Transthyretin-related amyloidoses and the heart: a clinical overview.
Trapping of palindromic ligands within native transthyretin prevents amyloid formation.
Treatment of cardiac transthyretin amyloidosis: an update.
Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials.
Treatment success in hereditary transthyretin amyloidosis.
True, true unrelated? Coexistence of Waldenström macroglobulinemia and cardiac transthyretin amyloidosis.
Tuning transthyretin amyloidosis inhibition properties of iododiflunisal by combinatorial engineering of the nonsalicylic ring substitutions.
Two transthyretin mutations (glu42gly, his90asn) in an Italian family with amyloidosis.
Two types of amyloidosis presenting in a single patient: a case series.
Two-tiered DNA-based diagnosis of transthyretin amyloidosis reveals two novel point mutations.
Tyr78Phe Transthyretin Mutation with Predominant Motor Neuropathy as the Initial Presentation.
Ultrastructure in Transthyretin Amyloidosis: From Pathophysiology to Therapeutic Insights.
Uncovering the Mechanism of Aggregation of Human Transthyretin.
Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis.
Understanding the Disease Course and Therapeutic Benefit of Tafamidis Across Real-World Studies of Hereditary Transthyretin Amyloidosis with Polyneuropathy: A Proof of Concept for Integrative Data Analytic Approaches.
Unexplained cardiac failure leading to the identification of a Belgian family affected by hereditary amyloidosis.
Unfolding and aggregation of transthyretin by the truncation of 50 N-terminal amino acids.
Unfolding Cardiac Amyloidosis - From Pathophysiology to Cure.
Unmasking Early Wild-Type Transthyretin Amyloidosis Cardiomyopathy in a Patient With Refractory Atrial Fibrillation and Unremarkable Cardiac Imaging.
Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.
Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction.
Update in recent clinical trials in heart failure.
Upper limb onset of hereditary transthyretin amyloidosis is common in non-endemic areas.
Uptake of aggregating transthyretin by fat body in a Drosophila model for TTR-associated amyloidosis.
Use of a microchip device coupled with mass spectrometry for ligand screening of a multi-protein target.
Use of fluorine-18 sodium fluoride for the diagnosis of transthyretin cardiac amyloidosis: The birth of a new technique.
Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin.
Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis.
Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis.
Usefulness of Combining Electrocardiographic and Echocardiographic Findings and Brain Natriuretic Peptide in Early Detection of Cardiac Amyloidosis in Subjects With Transthyretin Gene Mutation.
Usefulness of plasma B-type natriuretic peptide as a prognostic marker of cardiac function in senile systemic amyloidosis and in familial amyloidotic polyneuropathy.
Value of natriuretic peptides and tissue Doppler imaging in the estimation of left ventricular filling pressure in patients with cardiac amyloidosis.
Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients.
Variant transthyretin (TTR) amyloidosis in Argentina. Detection of the trait by electrospray ionization mass spectrometry of lyophilized TTR immunoprecipitate.
Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans.
Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis.
Vascular endothelial growth factor helps differentiate neuropathies in rare plasma cell dyscrasias.
Visualization of multiple organ amyloid involvement in systemic amyloidosis using (11)C-PiB PET imaging.
Vitreal deposits in Val71Ala transthyretin amyloidosis.
Vitreous amyloidosis after liver transplantation in patients with familial amyloid polyneuropathy: ocular synthesis of mutant transthyretin.
Vitreous amyloidosis associated with homozygosity for the transthyretin methionine-30 gene.
Vitreous amyloidosis in alanine 71 transthyretin mutation.
Vitreous amyloidosis in familial amyloidotic polyneuropathy. Report of a case with the Val30Met transthyretin mutation.
Vitreous amyloidosis in two large mainland Chinese kindreds resulting from transthyretin variant Lys35Thr and Leu55Arg.
Vitreous amyloidosis in two sisters as the indication of transthyretin-related familial form of systemic amyloidosis among liver transplantation candidates.
Vitreous amyloidosis with autonomic neuropathy of the digestive tract associated with a novel transthyretin p.Gly87Arg variant in a Bangladeshi patient: a case report.
Vitreous amyloidosis without systemic or familial involvement.
When and how do patients with cardiac amyloidosis die?
Where Neurosurgery Meets Heart Failure: A Case Report of a Patient with Amyloid Transthyretin Wild Type in the Ligamentum Flavum and Cardiac Tissue with Bilateral Carpal Tunnel Syndrome.
White matter disorders with autosomal dominant heredity: a review with personal clinical case studies and their MRI findings.
Why are some amyloidoses systemic? Does hepatic "chaperoning at a distance" prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis?
Widespread Cardiac and Vasomotor Autonomic Dysfunction in Non-Val30Met Hereditary Transthyretin Amyloidosis.
Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies.
Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging.
Yield of Noncardiac Biopsy for the Diagnosis of Transthyretin Cardiac Amyloidosis.
[18F]-NaF PET/CT imaging in cardiac amyloidosis.
[A selection of advances in neuromuscular medicine].
[AA Amyloidosis: recent knowledges on pathophysiology]
[Aged onset of amyloidosis caused by transthyretin gene mutations]
[Amyloid neuropathy resulting from an unknown protein.]
[Amyloidosis and aging]
[Amyloidosis and neurological disorders: Treatable amyloidosis].
[Antisense therapies for neurological diseases].
[Application to transthyretin analysis]
[Bone seeking tracers' scintigraphy for the diagnosis of transthyretin cardiac amyloidosis].
[Cardiac amyloidosis: How to recognize them and manage them?]
[Cardiac amyloidosis: Recent advances in the diagnosis and therapy].
[Cardiac amyloidosis: review of the literature]
[Cardiac amyloidosis]
[Cardiac manifestations of amyloidosis by deposits of transthyretin and apolipoprotein A1. Report of 3 families]
[Classification of amyloidosis].
[Clinical characteristics of Hungarian-type familial meningo-cerebrovascular amyloidosis]
[Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy].
[Familial amyloidosis]
[Familial transthyretin amyloidosis with Gly47Arg mutation and cardiac involvement: a case report].
[Familial transthyretin amyloidosis]
[Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know]
[Gene therapy in familial amyloidotic polyneuropathy by single-stranded oligonucleotides (SSOs)]
[Hereditary amyloid cardiomyopathy related to a mutation at transthyretin protein number 111. A clinical, genetic and echocardiographic study of an affected Danish family]
[Hereditary cardiac amyloidosis with transthyretin mutations : A cause of sudden death.]
[Histological and immunohistochemical examinations in the diagnosis of hepatic amyloidosis].
[Indications for simultaneous origin of a German and American family with type II hereditary amyloid neuropathy]
[Multiple nodular pulmonary amyloidosis complicated with Sjögren syndrome]
[Non-invasive diagnosis of cardiac amyloidosis due to transthyretin. Case report].
[Novel tool for diagnosis of amyloidosis]
[Optimization of the immunohistochemical diagnosis of AL amyloidosis using novel antibodies].
[Pathogenesis and therapy for transthyretin related amyloidosis]
[Perioperative management for liver transplant in a patient with familial amyloid polyneuropathy with heart involvement.]
[Problems of diagnostics and treatment of transtiretinum amyloidosis with destruction of the heart in the elderly: Clinical experience.]
[Progress in the diagnosis and treatment of cardiac amyloidosis].
[Senile systemic amyloidosis: definition, diagnosis, why thinking about?].
[Senile systemic amyloidosis].
[The informative value of oral mucosal biopsy for the diagnosis of systemic amyloidosis].
[Transthyretin amyloidoses]
[Transthyretin amyloidosis in a cohort of old and very old patients with chronic heart failure].
[Transthyretin Arg-83 mutation in vitreous amyloidosis]
[Transthyretin-related amyloidotic cardiomyopathy: looking for the etiological treatment].
[What gnaws at the heart and gets on the nerves].
Amyloidosis, Familial
99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy.
A case of hereditary amyloidosis transthyretin variant Met 30 with amyloid cardiomyopathy, less polyneuropathy, and the presence of giant cells.
A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options.
A new mutation (TTR Ala-47) in the transthyretin gene associated with hereditary amyloidosis.
A new transthyretin mutation associated with amyloid cardiomyopathy.
A new transthyretin variant (Ser23Asn) associated with familial amyloidosis in a Portuguese patient.
A Patient With Hereditary ATTR and a Novel AGel p.Ala578Pro Amyloidosis.
A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers.
A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population.
Advanced glycation end products (AGE) and the receptor for AGE are present in gastrointestinal tract of familial amyloidotic polyneuropathy patients but do not induce NF-kappaB activation.
Ageing and amyloid fibrillogenesis: lessons from apolipoprotein AI, transthyretin and islet amyloid polypeptide.
Amyloid diseases of the heart: current and future therapies.
Amyloid fibril protein in familial amyloidosis with cranial neuropathy and corneal lattice dystrophy (FAP type IV) is related to transthyretin.
An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis.
Anesthetic management of a combined heart and liver transplantation in an amyloidotic patient: a case report.
Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity.
Capture of a dimeric intermediate during transthyretin amyloid formation.
Cardiac amyloidosis with gastrointestinal involvement: a case report.
Cardiac amyloidosis: a review and report of a new transthyretin (prealbumin) variant.
Clinical manifestations in hereditary amyloidosis with the variant Glu54Gln transthyretin.
Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis.
Current treatment in cardiac amyloidosis.
Current trends in diagnosis and management of cardiac amyloidosis.
Description of transthyretin S50A, S52P and G47A mutations in familial amyloidosis polyneuropathy.
Diagnosis and therapeutic approaches to transthyretin amyloidosis.
Discovery of ?-Mangostin as an Amyloidogenesis Inhibitor.
Early diagnostic tools in hereditary amyloidosis related to transthyretin (hATTR) V30M autonomic neuropathy.
Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy.
Electrochemical skin conductance in hereditary amyloidosis related to transthyretin V30M - a promising tool to assess treatment efficacy?
Electromyographic findings in transthyretin (TTR)-related familial amyloid polyneuropathy (FAP).
Erythropoietin production by distal nephron in normal and familial amyloidotic adult human kidneys.
Familial amyloidosis in a large Spanish kindred resulting from a D38V mutation in the transthyretin gene.
Familial amyloidosis with polyneuropathy type 1 caused by transthyretin mutation Val50Met (Val30Met): 4 cases in a non-endemic area.
Generation of familial amyloidotic polyneuropathy-specific induced pluripotent stem cells.
Haplotype analysis of common transthyretin mutations.
Hereditary amyloidosis related to transthyretin V30M: disease progression in treated and untreated patients.
Hereditary amyloidosis with cardiomyopathy caused by the novel variant transthyretin A36D.
Homozygosity and heterozygosity for the transthyretin Leu64 mutation: clinical, biochemical and molecular findings.
Identification of transthyretin variants by sequential proteomic and genomic analysis.
Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients.
Inhibition of transthyretin-met30 expression using Inosine(15.1)-Hammerhead ribozymes in cell culture.
Inosine(15.1) hammerhead ribozymes for targeting the transthyretin-30 mutation.
Investigation of AGE, their receptor and NF-kappaB activation and apoptosis in patients with ATTR and Gelsolin amyloidosis.
Liver transplantation for hereditary transthyretin amyloidosis.
Long-term effects of liver transplantation on small-fiber dysfunction in Japanese transthyretin (ATTR) V30M hereditary amyloidosis with polyneuropathy (FAP).
Mechanisms of transthyretin amyloidogenesis. Antigenic mapping of transthyretin purified from plasma and amyloid fibrils and within in situ tissue localizations.
Mutation and transcription analysis of transthyretin gene in Italian families with hereditary amyloidosis: a putative novel hot spot' in codon 47.
Normal transthyretin and synthetic transthyretin fragments form amyloid-like fibrils in vitro.
Novel methods for detecting amyloidogenic proteins in transthyretin related amyloidosis.
Novel transthyretin missense mutation (Thr34) in an Italian family with hereditary amyloidosis.
Ocular Manifestations of Familial Transthyretin Amyloidosis.
Orthotopic liver transplantation for hereditary fibrinogen amyloidosis.
Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients.
Postmortem findings in two familial amyloidosis patients with transthyretin variant Asp38Ala.
Pupil abnormality in amyloidosis with autonomic neuropathy.
Quantitative analysis of post-translational modifications in human serum transthyretin associated with familial amyloidotic polyneuropathy by targeted LC-MS and intact protein MS.
Regional difference and similarity of familial amyloidosis with polyneuropathy in France.
Screening and biochemical characterization of transthyretin variants in the Portuguese population.
Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation.
Speckle Tracking and Transthyretin Amyloid Cardiomyopathy.
STT3B-dependent posttranslational N-glycosylation as a surveillance system for secretory protein.
The premortem recognition of systemic senile amyloidosis with cardiac involvement.
The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology.
The transthyretin cDNA sequence is normal in transthyretin-derived senile systemic amyloidosis.
The use of intravitreal ranibizumab to treat neovascular glaucoma because of retinal amyloid angiopathy in familial amyloidosis transthyretin v30m related.
Three Turkish families with different transthyretin mutations.
Transthyretin (prealbumin) gene in human primary hepatic cancer.
Transthyretin amyloidosis: a little history of hereditary amyloidosis.
Transthyretin amyloidosis: a tale of weak interactions.
Transthyretin Cardiac Amyloidosis.
Transthyretin proteins regulate angiogenesis by conferring different molecular identities to endothelial cells.
Transthyretin Tyr69-to-Ile mutation (double-nucleotide substitution in codon 69) in a Japanese familial amyloidosis patient with cardiomyopathy and carpal tunnel syndrome.
TRANSTHYRETIN V30M FAMILIAL AMYLOIDOSIS PRESENTING AS ISOLATED RETINAL ANGIOPATHY.
Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment.
Transthyretin-Related Hereditary Amyloidosis in a Chinese Family with TTR Y114C Mutation.
TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance?
Two transthyretin variants (TTR Ala-49 and TTR Gln-89) in two Sicilian kindreds with hereditary amyloidosis.
Tyr78Phe Transthyretin Mutation with Predominant Motor Neuropathy as the Initial Presentation.
Vitreous amyloidosis without systemic or familial involvement.
[Can amyloidosis regress?]
[Clinical case: non familial vitreous amyloidosis].
[Clinical characteristics of Hungarian-type familial meningo-cerebrovascular amyloidosis]
[Hereditary amyloidoses associated with transthyretin mutations]
[Neurology].
Anemia
Low erythropoietin production in familial amyloidosis TTR V30M is not related with renal congophilic amyloid deposition. A clinicopathologic study of twelve cases.
Unwanted road to anaemia in transthyretin familial amyloid polyneuropathy may continue irrespective of tafamidis treatment.
Angina, Unstable
[Difference expressed protein study on unstable angina blood-stasis syndrome by fluorescence labelling method]
Aortic Valve Stenosis
Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg?
Dangerous relationships: aortic stenosis and transthyretin cardiac amyloidosis.
Estimating cancer risk from 99mTc pyrophosphate imaging for transthyretin cardiac amyloidosis.
Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement.
Prognostic Significance of Occult Transthyretin Cardiac Amyloidosis in Patients With Severe Aortic Stenosis Undergoing Surgical Aortic Valve Replacement: An Unrecognized Disease Modifier.
Recognizing Transthyretin Cardiac Amyloidosis in Patients With Aortic Stenosis: Impact on Prognosis.
Transthyretin cardiac amyloid and aortic stenosis in the elderly, the role of nuclear imaging.
Transthyretin Cardiac Amyloidosis and Aortic Stenosis: Connection and Therapeutic Implications.
Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.
Arrhythmias, Cardiac
Cardiac amyloidosis: An underdiagnosed/underappreciated disease.
Continuous development of arrhythmia is observed in Swedish transplant patients with familial amyloidotic polyneuropathy (amyloidogenic transthyretin Val30Met variant).
Reduced left atrial myocardial deformation irrespective of cavity size: a potential cause for atrial arrhythmia in hereditary transthyretin amyloidosis.
Arteriosclerosis
Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies.
Arthritis
Autoimmune response to transthyretin in juvenile idiopathic arthritis.
Arthritis, Experimental
Proteins of rat serum V: adjuvant arthritis and its modulation by nonsteroidal anti-inflammatory drugs.
Arthritis, Juvenile
Autoimmune response to transthyretin in juvenile idiopathic arthritis.
Arthritis, Rheumatoid
Identification of Autoantibodies against Transthyretin for the Screening and Diagnosis of Rheumatoid Arthritis.
Retraction: Identification of Autoantibodies against Transthyretin for the Screening and Diagnosis of Rheumatoid Arthritis.
Transthyretin as a potential serological marker for the diagnosis of patients with early rheumatoid arthritis.
Astrocytoma
Transthyretin receptors on human astrocytoma cells.
Ataxia
A novel amyloidogenic transthyretin variant, Gly53Ala, associated with intermittent headaches and ataxia.
Atherosclerosis
Inflammatory and Molecular Pathways in Heart Failure-Ischemia, HFpEF and Transthyretin Cardiac Amyloidosis.
Atrial Fibrillation
Atrial Fibrillation and Central Nervous Complications in Liver Transplanted Hereditary Transthyretin Amyloidosis Patients.
Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology.
Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience.
Unmasking Early Wild-Type Transthyretin Amyloidosis Cardiomyopathy in a Patient With Refractory Atrial Fibrillation and Unremarkable Cardiac Imaging.
Bile Duct Neoplasms
Plasma retinol transport system and taste acuity in patients with obstructive jaundice.
Blindness
Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
Brain Ischemia
Cerebrospinal fluid transthyretin neuroprotection in a mouse model of brain ischemia.
Combined proteomic approach with SELDI-TOF-MS and peptide mass fingerprinting identified the rapid increase of monomeric transthyretin in rat cerebrospinal fluid after transient focal cerebral ischemia.
Evidence for synergistic action of transthyretin and IGF-I over the IGF-I receptor.
Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
Transthyretin provides trophic support via megalin by promoting neurite outgrowth and neuroprotection in cerebral ischemia.
Brain Neoplasms
Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation.
[Immunohistochemical study on distribution of transthyretin in normal human brain tissue and tumors]
Breast Neoplasms
Amyloidosis of the Breast: Three Different and Unusual Presentations of a Rare Entity.
Biomarkers of phenethyl isothiocyanate-mediated mammary cancer chemoprevention in a clinically relevant mouse model.
PEL: an unbiased method for estimating age-dependent genetic disease risk from pedigree data unselected for family history.
Two-dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditions.
Bronchiectasis
Nutritional depletion in patients on long-term oxygen therapy and/or home mechanical ventilation.
Bronchitis
[Bronchoalveolar lavage. The humoral parameter spectrum in bronchial carcinoma and chronic bronchitis]
Bronchitis, Chronic
[Bronchoalveolar lavage. The humoral parameter spectrum in bronchial carcinoma and chronic bronchitis]
Brugada Syndrome
Therapeutic Strategies Targeting Inherited Cardiomyopathies.
Bulbo-Spinal Atrophy, X-Linked
The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage.
Carcinogenesis
HCC Specific Protein Network Involving Interactions of EGFR with A-Raf and Transthyretin: Experimental Analysis and Computational Biology Correlates.
Carcinoma
Identification of novel diagnostic markers for choroid plexus tumors: a microarray-based approach.
The choroid plexus carcinomas of childhood: histopathology, immunocytochemistry and clinicopathological correlations.
The use of immunomorphology to differentiate choroid plexus tumors from metastatic carcinomas.
Transthyretin and cystatin C are catabolized in proximal tubular epithelial cells and the proteins are not useful as markers for renal cell carcinomas.
Transthyretin, identified by proteomics, is overabundant in pancreatic juice from pancreatic carcinoma and originates from pancreatic islets.
Transthyretin--an explanation of "anomalous" serum thyroid hormone values in severe illness?
Tumors of the choroid plexus.
[Prognostic markers in the histopathological diagnosis of tumors of the choroid plexus]
Carcinoma, Bronchogenic
Tracheobronchial amyloidosis.
[Bronchoalveolar lavage. The humoral parameter spectrum in bronchial carcinoma and chronic bronchitis]
Carcinoma, Embryonal
Induction of the expression of retinol-binding protein and transthyretin in F9 embryonal carcinoma cells differentiated to embryoid bodies.
Carcinoma, Hepatocellular
Adenovirus-mediated hepatocyte nuclear factor-4alpha overexpression maintains liver phenotype in cultured rat hepatocytes.
Clinical significance of serum transthyretin level in patients with hepatocellular carcinoma.
Decreased expression of hepatocyte nuclear factor 3 alpha during the acute-phase response influences transthyretin gene transcription.
Deficiency of 5-hydroxyisourate hydrolase causes hepatomegaly and hepatocellular carcinoma in mice.
Differential regulation of hepatocyte-enriched transcription factors explains changes in albumin and transthyretin gene expression among hepatoma cells.
Functional activity of hepatocyte nuclear factor-1 is specifically decreased in amino acid-limited hepatoma cells.
Novel mutations in transthyretin gene associated with hepatocellular carcinoma.
Receptor-mediated uptake and internalization of transthyretin.
Studies on the synthesis and secretion of transthyretin by the human hepatoma cell line Hep G2.
Carcinoma, Non-Small-Cell Lung
Prognostic impact of serum transthyretin in patients with non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
Postoperative recurrence of epithelial ovarian cancer patients and chemoresistance related protein analyses.
Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
Carcinoma, Renal Cell
Amyloid and peripheral nervous system disease.
Receptor-mediated uptake and internalization of transthyretin.
Transthyretin and cystatin C are catabolized in proximal tubular epithelial cells and the proteins are not useful as markers for renal cell carcinomas.
Cardiac Conduction System Disease
Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy.
Cardiomegaly
Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis.
Cardiomyopathies
6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR).
99mTechnetium pyrophosphate scintigraphy with cadmium zinc telluride cameras is a highly sensitive and specific imaging modality to diagnose transthyretin cardiac amyloidosis.
A case of hereditary amyloidosis transthyretin variant Met 30 with amyloid cardiomyopathy, less polyneuropathy, and the presence of giant cells.
A case of transthyretin amyloidosis with myopathy, neuropathy, and cardiomyopathy resulting from an exceedingly rare mutation transthyretin Ala120Ser (c.418G?>?T, p.Ala140Ser).
A clinical, echocardiographic and genetic characterization of a Danish kindred with familial amyloid transthyretin methionine 111 linked cardiomyopathy.
A Danish kindred with familial amyloid cardiomyopathy revisited: identification of a mutant transthyretin-methionine111 variant in serum from patients and carriers.
A Heart too Stiff to Beat: A Case of Familial Transthyretin Amyloidosis Cardiomyopathy.
A look into amyloid formation by transthyretin: aggregation pathway and a novel kinetic model.
A new amyloidogenic transthyretin variant (Val122Ala) found in a compound heterozygous patient.
A new staging system for cardiac transthyretin amyloidosis.
A new transthyretin mutation associated with amyloid cardiomyopathy.
A new transthyretin variant (Glu61Gly) associated with cardiomyopathy.
A new transthyretin variant (Ser23Asn) associated with familial amyloidosis in a Portuguese patient.
A novel ATTR L32V mutation causes familial amyloid polyneuropathy in a Bolivian family.
A novel variant of transthyretin (Glu89Lys) associated with familial amyloidotic polyneuropathy.
A rare transthyretin mutation (Asp18Glu) associated with cardiomyopathy.
A transthyretin variant, Asp18Asn, associated with amyloid cardiomyopathy: a new African-American variant?
Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosis.
Amyloid cardiomyopathy in a large integrated health care system.
Amyloid Cardiomyopathy in Hereditary Transthyretin V30M Amyloidosis - Impact of Sex and Amyloid Fibril Composition.
Amyloid Cardiomyopathy in the Rare Transthyretin Tyr78Phe Mutation.
Amyloid cardiomyopathy: a hidden heart failure cause that is often misdiagnosed.
Amyloid Fibril Composition as a Predictor of Development of Cardiomyopathy After Liver Transplantation for Hereditary Transthyretin Amyloidosis.
Amyloid Polyneuropathy Caused By Wild-Type Transthyretin.
Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants.
An Italian family with Ala-47 transthyretin mutation associated with cardiomyopathy and polyneuropathy.
Burden of hereditary transthyretin amyloidosis on quality of life.
Cardiac amyloidosis: An underdiagnosed/underappreciated disease.
Cardiac amyloidosis: from clinical suspicion to morphological diagnosis.
Cardiac amyloidosis: Updates in diagnosis and management.
Cardiac transthyretin amyloidosis.
Cardiomyopathy in a Japanese family with the Glu61Lys transthyretin variant: a new phenotype.
Cardiomyopathy in Swedish patients with the Gly53Glu and His88Arg transthyretin variants.
Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers.
Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy.
Combined heart and liver transplantation for familial amyloidotic neuropathy: considerations from the hepatic point of view.
Contributions of Animal Models to the Mechanisms and Therapies of Transthyretin Amyloidosis.
Coronary ectasia in amyloid cardiomyopathy and neuropathy due to the transthyretin mutation c.323A>G.
Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients.
Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis.
Dietary curcumin counteracts extracellular transthyretin deposition: insights on the mechanism of amyloid inhibition.
Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center's experience.
Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis?
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
Estimating the Prevalence of Transthyretin Amyloid Cardiomyopathy in a Large In-Hospital Database in Japan.
Etiology of Amyloidosis Determines Myocardial 99mTc-DPD Uptake in Amyloidotic Cardiomyopathy.
Evaluation of tafamidis as first-line therapeutic agent for transthyretin familial amyloidotic polyneuropathy.
Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.
Familial amyloid polyneuropathy.
Familial wild-type transthyretin cardiomyopathy.
Fluorotryptophan incorporation modulates the structure and stability of transthyretin in a site-specific manner.
FRET studies of various conformational states adopted by transthyretin.
Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis.
Glycosaminoglycans in extracts of cardiac amyloid fibrils from familial amyloid cardiomyopathy of Danish origin related to variant transthyretin Met 111.
Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study.
Green tea halts progression of cardiac transthyretin amyloidosis: an observational report.
Guideline of transthyretin-related hereditary amyloidosis for clinicians.
Hereditary amyloidosis with cardiomyopathy caused by the novel variant transthyretin A36D.
Hereditary ATTR Amyloidosis with Cardiomyopathy Caused by the Novel Variant Transthyretin Y114S (p.Y134S).
Identification of a novel TTR Gly67Glu mutant and the first case series of familial transthyretin amyloidosis in Hong Kong Chinese.
Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure?
Imaging of cardiac amyloidosis by (99m)Tc-PYP scintigraphy.
Inflammatory and Molecular Pathways in Heart Failure-Ischemia, HFpEF and Transthyretin Cardiac Amyloidosis.
Involvement of human monogenic cardiomyopathy genes in experimental polygenic cardiac hypertrophy.
Isolated heart transplantation for familial transthyretin (TTR) V122I cardiac amyloidosis.
Kinetic analysis of the multistep aggregation pathway of human transthyretin.
Late-onset and fast progressive neuropathy and cardiomyopathy in Val32Ala transthyretin gene mutation.
Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy.
Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.
Methods to evaluate the inhibition of TTR fibrillogenesis induced by small ligands.
Molecular diagnosis of the transthyretin (TTR) Met111 mutation in familial amyloid cardiomyopathy of Danish origin.
Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.
New pathological insights into cardiac amyloidosis: implications for non-invasive diagnosis.
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.
Noninvasive diagnosis of hereditary transthyretin-related cardiac amyloidosis: A case report.
Novel drugs targeting transthyretin amyloidosis.
Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management.
Orthotopic liver transplantation for familial amyloidotic polyneuropathy: a pathological study.
Outcome in patients treated with isolated liver transplantation for familial transthyretin amyloidosis to prevent cardiomyopathy.
Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.
Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy).
Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity.
Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness.
Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type.
Progression of cardiomyopathy and neuropathy after liver transplantation in a patient with familial amyloidotic polyneuropathy caused by tyrosine-77 transthyretin variant.
Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS).
Purification and characterization of amyloid-related transthyretin associated with familial amyloidotic cardiomyopathy.
Quaternary structure, aggregation and cytotoxicity of transthyretin.
Rate of progression of transthyretin amyloidosis.
Rational design of potent human transthyretin amyloid disease inhibitors.
Real-world versus trial patients with transthyretin amyloid cardiomyopathy.
Recent advances in the diagnosis and management of cardiac amyloidosis.
Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy.
Retinal microangiopathy as an initial manifestation of familial amyloid cardiomyopathy associated with transthyretin e89k mutation.
Retrospective molecular detection of Transthyretin Met 111 mutation in a Danish kindred with familial amyloid cardiomyopathy, using DNA from formalin-fixed and paraffin-embedded tissues.
Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.
Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses.
Speckle Tracking and Transthyretin Amyloid Cardiomyopathy.
Spectrum of Restrictive and Infiltrative Cardiomyopathies: Part 1 of a 2-Part Series.
Stabilizing Transthyretin to Treat ATTR Cardiomyopathy.
Structural insights into a zinc-dependent pathway leading to Leu55Pro transthyretin amyloid fibrils.
Structure of the Val122Ile variant transthyretin - a cardiomyopathic mutant.
Structure-based analysis of A19D, a variant of transthyretin involved in familial amyloid cardiomyopathy.
Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides.
Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
Synthesis and structural analysis of halogen substituted fibril formation inhibitors of Human Transthyretin (TTR).
Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
Tafamidis for Transthyretin Amyloid Cardiomyopathy.
Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?
Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population.
The "Wagshurst study": p.Val40Ile transthyretin gene variant causes late-onset cardiomyopathy.
The amyloidogenic V122I transthyretin variant in elderly black Americans.
The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin.
The flavonoid luteolin, but not luteolin-7-O-glucoside, prevents a transthyretin mediated toxic response.
The polyphenol Oleuropein aglycone hinders the growth of toxic transthyretin amyloid assemblies.
The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis.
Therapeutic Strategies Targeting Inherited Cardiomyopathies.
Therapy of Transthyretin Cardiomyopathy.
Three siblings of familial amyloid cardiomyopathy with isoleucine-50 transthyretin mutation.
Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.
Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy.
Transthyretin Cardiac Amyloidosis.
Transthyretin Glu54Leu - an unknown mutation within the Swedish population associated with amyloid cardiomyopathy and a unique fibril type.
Transthyretin related familial amyloid polyneuropathy.
Transthyretin RNA profiling in livers from transplanted patients affected by familial amyloidotic polyneuropathy, and identification of a dual transcription start point.
Transthyretin Tyr69-to-Ile mutation (double-nucleotide substitution in codon 69) in a Japanese familial amyloidosis patient with cardiomyopathy and carpal tunnel syndrome.
Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans.
Transthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy.
Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials.
Treatment of transthyretin cardiomyopathy with a TTR-specific antisense oligonucleotide (IONIS-TTRRx).
Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy.
Two Siblings Diagnosed to Have Transthyretin-related Familial Amyloid Cardiomyopathy Around the Same Time at Different Hospitals.
Unmasking Early Wild-Type Transthyretin Amyloidosis Cardiomyopathy in a Patient With Refractory Atrial Fibrillation and Unremarkable Cardiac Imaging.
Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis.
Verification of the transthyretin Met 111 mutation in familial amyloid cardiomyopathy of Danish origin by DNA sequencing.
Wild-Type Transthyretin Amyloid Cardiomyopathy: A Missed Cause of Heart Failure With Preserved Ejection Fraction With Evolving Treatment Implications.
Yield of Noncardiac Biopsy for the Diagnosis of Transthyretin Cardiac Amyloidosis.
[Hereditary amyloid cardiomyopathy related to a mutation at transthyretin protein number 111. A clinical, genetic and echocardiographic study of an affected Danish family]
[Transthyretin amyloidoses]
[Transthyretin gene V30M, H90N, and del9 mutations in cardiomyopathy patients from St. Petersburg].
Cardiomyopathy, Hypertrophic
Amyloid heart disease mimicking hypertrophic cardiomyopathy.
Can echocardiography and ECG discriminate hereditary transthyretin V30M amyloidosis from hypertrophic cardiomyopathy?
Left Atrial Morphology, Size and Function in Patients With Transthyretin Cardiac Amyloidosis and Primary Hypertrophic Cardiomyopathy?- Comparative Strain Imaging Study.
Transthyretin amyloidosis in a septuagenarian masquerading as hypertrophic cardiomyopathy: the importance of multimodality imaging.
Transthyretin Amyloidosis Mimicking Obstructive Hypertrophic Cardiomyopathy: A Great Imitator.
Transthyretin amyloidosis: a phenocopy of hypertrophic cardiomyopathy.
[Liver transplantation in familial amyloid polyneuropathy. Case report and review of the literature]
Cardiomyopathy, Restrictive
A clinical, echocardiographic and genetic characterization of a Danish kindred with familial amyloid transthyretin methionine 111 linked cardiomyopathy.
Cardiac amyloidosis associated with a novel transthyretin aspartic acid-18 glutamic acid de novo mutation.
Cardiac amyloidosis associated with the transthyretin Ile122 mutation in a Caucasian family.
Demyelinating Neuropathy in a Patient Treated With Revusiran for Transthyretin (Thr60Ala) Amyloidosis.
Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis.
Hereditary Amyloidosis with Recurrent Lung Infiltrates.
Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier?
Myocardial Contraction Fraction by M-Mode Echocardiography Is Superior to Ejection Fraction in Predicting Mortality in Transthyretin Amyloidosis.
Novel drugs targeting transthyretin amyloidosis.
Senile cardiac amyloidosis associated with homozygosity for a transthyretin variant (ILE-122).
Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides.
Transthyretin Ile 122 and cardiac amyloidosis in African-Americans. 2 case reports.
[Bone seeking tracers' scintigraphy for the diagnosis of transthyretin cardiac amyloidosis].
[Hereditary amyloid cardiomyopathy related to a mutation at transthyretin protein number 111. A clinical, genetic and echocardiographic study of an affected Danish family]
Cardiovascular Diseases
Acute Phase Reactants as Novel Predictors of Cardiovascular Disease.
Carpal Tunnel Syndrome
A case study of likely wild-type cardiac transthyretin amyloidosis causing rapid deterioration.
A new transthyretin variant (Glu61Gly) associated with cardiomyopathy.
A novel transthyretin Lys70Glu (p.Lys90Glu) mutation presenting with vitreous amyloidosis and carpal tunnel syndrome.
A transthyretin mutation (Tyr78Phe) associated with peripheral neuropathy, carpal tunnel syndrome and skin amyloidosis.
Amyloid and peripheral nervous system disease.
Cardiomyopathy in a Japanese family with the Glu61Lys transthyretin variant: a new phenotype.
Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?
Effect of synovial transthyretin amyloid deposition on preoperative symptoms and postoperative recovery of median nerve function among patients with idiopathic carpal tunnel syndrome.
Establishing and validating the fluorescent amyloid ligand h-FTAA (heptamer formyl thiophene acetic acid) to identify transthyretin amyloid deposits in carpal tunnel syndrome.
Familial amyloid polyneuropathy in a Spanish family with a transthyretin deletion (deltaVal 122) presenting with carpal tunnel syndrome.
Familial amyloidotic polyneuropathy presenting with carpal tunnel syndrome and a new transthyretin mutation, asparagine 70.
Familial carpal tunnel syndrome due to amyloidogenic transthyretin His 114 variant.
High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly.
New mutant gene (transthyretin Arg 58) in cases with hereditary polyneuropathy detected by non-isotope method of single-strand conformation polymorphism analysis.
Nodular cutaneous amyloidosis and carpal tunnel syndrome due to the amyloidogenic transthyretin His 114 variant.
Non-senile wild-type transthyretin systemic amyloidosis presenting as bilateral carpal tunnel syndrome.
Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness.
Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses.
The significance of carpal tunnel syndrome in transthyretin Val30Met familial amyloid polyneuropathy.
Transthyretin Tyr69-to-Ile mutation (double-nucleotide substitution in codon 69) in a Japanese familial amyloidosis patient with cardiomyopathy and carpal tunnel syndrome.
Upper limb neuropathy such as carpal tunnel syndrome as an initial manifestation of ATTR Val30Met familial amyloid polyneuropathy.
Where Neurosurgery Meets Heart Failure: A Case Report of a Patient with Amyloid Transthyretin Wild Type in the Ligamentum Flavum and Cardiac Tissue with Bilateral Carpal Tunnel Syndrome.
[Carpal tunnel syndrome and ATTR-amyloidosis].
Cataract
Albumin and transthyretin as risk factors for cataract: the POLA study.
Identification of vitreous proteins in retinopathy of prematurity.
Celiac Disease
Transthyretin: a marker for celiac disease activity.
Cerebral Amyloid Angiopathy
Characterization of a transthyretin-related amyloid fibril protein from cerebral amyloid angiopathy in type I familial amyloid polyneuropathy.
Clinical aspects of cerebral amyloid angiopathy.
Coexistence of transthyretin- and A?-type cerebral amyloid angiopathy in a patient with hereditary transthyretin V30M amyloidosis.
Comparison of clinical features in transient focal neurological episodes between hereditary transthyretin type and A? type cerebral amyloid angiopathy.
Effect of liver transplantation on transthyretin Tyr114Cys-related cerebral amyloid angiopathy.
Recurrent subarachnoid bleeding and superficial siderosis in a patient with histopathologically proven cerebral amyloid angiopathy.
[Cerebral amyloid angiopathies]
[Cerebral amyloid angiopathy]
[Hereditary cerebral amyloid angiopathies]
Cerebral Amyloid Angiopathy, Familial
Effect of liver transplantation on transthyretin Tyr114Cys-related cerebral amyloid angiopathy.
Cerebral Hemorrhage
Effect of liver transplantation on transthyretin Tyr114Cys-related cerebral amyloid angiopathy.
Protein aging Extracellular amyloid formation and intracellular repair.
Cerebrospinal Fluid Rhinorrhea
Microfluidic validation of diagnostic protein markers for spontaneous cerebrospinal fluid rhinorrhea.
Cerebrovascular Disorders
Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy.
ProApolipoprotein A1: a serum marker of brain metastases in lung cancer patients.
Charcot-Marie-Tooth Disease
The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage.
[What's new in hereditary neuropathies ?].
Cholangiocarcinoma
Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma.
Cholangitis
EUS-guided Biliary Drainage for Malignant Perihilar Biliary Strictures after Further Transpapillary Intervention Has Been Judged to Be Impossible or Ineffective.
Cholangitis, Sclerosing
Systemic but asymptomatic transthyretin amyloidosis 8 years after domino liver transplantation.
Cholestasis
Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer.
Impaired synthesis of retinol-binding protein and transthyretin in rat liver with bile duct obstruction.
Choriocarcinoma
CARRIER MEDIATED THYROID HORMONE TRANSPORT INTO PLACENTA BY PLACENTAL TRANSTHYRETIN.
Oxygen concentration regulates expression and uptake of transthyretin, a thyroxine binding protein, in JEG-3 choriocarcinoma cells.
Choroid Plexus Neoplasms
Choroid plexus papilloma with stromal deposition of amyloid and elastic material.
Choroid plexus tumors in childhood. Histopathologic study and clinico-pathological correlation.
Clinicopathologic correlations in epithelial choroid plexus neoplasms: a study of 52 cases.
Transthyretin expression in medulloblastomas and medulloblastoma cell lines.
Transthyretin immunoreactivity in choroid plexus neoplasms and brain metastases.
Colorectal Neoplasms
Biomarkers for the early detection of relapses in metastatic colorectal cancers.
Detection of colorectal adenoma and cancer based on transthyretin and C3a-desArg serum levels.
Congenital Abnormalities
Naso-maxillary deformity due to frontonasal expression of human transthyretin gene in transgenic mice.